Csf1r-based chimeric proteins

ABSTRACT

The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.

PRIORITY

This application is a continuation of PCT/US18/20039, filed Feb. 27,2018. PCT/US18/20039 claims the benefit of U.S. Provisional ApplicationNo. 62/463,997, filed Feb. 27, 2017. The contents of the aforementionedapplications are incorporated herein by reference in their entirety.

INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY

This application contains a sequence listing. It has been submittedelectronically via EFS-Web as an ASCII text file entitled“SHK-002US_ST.txt”. The sequence listing is 93,032 bytes in size, andwas created on or about Dec. 18, 2018. The sequence listing is herebyincorporated by reference in its entirety.

TECHNICAL FIELD

The present invention relates, in part, to, chimeric proteins whichinclude the extracellular domain of colony stimulating factor 1 receptor(CSF1R) and their use in the treatment of diseases, such asimmunotherapies for cancer and/or inflammatory diseases.

BACKGROUND

Recent clinical data have demonstrated impressive patient responses toagents targeting immune coinhibitory molecules, including, for example,clinical trials that led to the approval of YERVOY, KEYTRUDA, andOPDIVO. These immunotherapies are collectively characterized ascheckpoint inhibitors, and unfortunately, these therapies only provideclinical benefit for ˜15-30% of cancer patients. One potential approachto improving clinical response rates for a broader population of cancerpatients includes combining a checkpoint inhibitor therapeutic withanother therapy. Such combinations, when applied using multipleindividual therapeutics, might lead to improved clinical benefit but arecumbersome to develop. Further, many immunotherapies are complicated bysevere side effects that significantly narrow a patient's therapeuticwindow for treatment.

There remains a need for novel methods and compositions that provideeffective immunotherapies, including consolidating multiple therapeuticmechanisms into single drugs.

SUMMARY

Accordingly, the present invention provides, in part, compositions andmethods that find use in cancer treatment by, for instance, overcomingmultiple suppressive mechanisms, in the tumor microenvironment, andstimulating immune antitumor mechanisms. Similarly, the compositions andmethods find use in treating an inflammatory disease. For instance, thepresent invention provides, in part, compositions and methods that allowfor dual targeting of suppressive myeloid populations by inhibitingCSF1/CSF1R signaling and activation of antigen-presenting cells bystimulating CD40/CD40L signaling. Such concurrent CSF1R blockade andCD40 agonism causes, inter alia, an overall decrease inimmunosuppressive cells and a shift toward a more inflammatory milieuand an increased antitumor effect.

In aspects, the present invention provides a heterologous chimericprotein comprising: (a) a first domain comprising a portion of colonystimulating factor 1 receptor (CSF1R) that is capable of binding a CSF1Rligand; (b) a second domain comprising a portion of CD40 Ligand (CD40L)that is capable of binding a CD40L receptor; and (c) a linker linkingthe first domain and the second domain. In aspects, the presentinvention provides methods of treating cancer with this heterologouschimeric protein. In aspects, the present invention provides methods oftreating an inflammatory disease with this heterologous chimericprotein.

In embodiments, the present invention provides a recombinant fusionprotein comprising a general structure of: N terminus-(a)-(b)-(c)-Cterminus, where (a) is a first domain comprising an extracellular domainof CSF1R that is at least 95% identical to the amino acid sequence ofSEQ ID NO: 2 and is capable of binding a CSF1R ligand, (b) is a linkerlinking the first domain and the second domain and comprising ahinge-CH2-CH3 Fc domain derived from human IgG4 (e.g. 95% identical tothe amino acid sequence of SEQ ID NO: 25, SEQ ID NO: 26, or SEQ ID NO:27, and (c) is a second domain comprising an extracellular domain ofCD40 ligand (CD40L) that is at least 95% identical to the amino acidsequence of SEQ ID NO: 4 and is capable of binding an CD40L receptor. Inembodiments, the present invention provides methods of treating cancerwith this heterologous chimeric protein. In embodiments, the presentinvention provides methods of treating an inflammatory disease with thisheterologous chimeric protein.

Any aspect or embodiment described herein can be combined with any otheraspect or embodiment as disclosed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A shows, without wishing to be bound by theory, a schematic for amechanism of action for the CSF1R-Fc-CD40L chimeric protein. FIG. 1Bshows a synapse that has formed by a chimeric protein between a tumorcell and a T cell. FIG. 1C shows the predicted secondary structure ofhuman CSF1R-Fc-CD40L, indicating how the three domains are predicted toform in their natural state. The CSF1R-Fc-CD40L chimeric protein'spredicted monomeric molecular weight is about 105.4 kDa.

FIG. 2 shows characterization by Western blot analysis of the threedomains of human CSF1R-Fc-CD40L under non-reducing/boiled,reducing/boiled, and reducing/deglycosylating/boiled (PNGase)conditions. The band sizes confirm the predicted monomeric molecularweight of about 105.4 kDa and suggests that the native state exists as aglycosylated dimer. As shown, lane 1, starting from the left in eachblot, is a protein molecular weight marker.

FIG. 3 shows functional enzyme linked immunosorbent assays (ELISAs)demonstrating binding of human CSF1R-Fc-CD40L to the targets of thethree domains individually (Fc—shown in the upper left, CSF1R—shown inthe upper right, and CD40L—shown in the lower left) as well as thecontemporaneous binding to both recombinant CSF1 and CD40—shown in thelower right. In the upper left panel, the top curve is IgG standard andthe bottom curve hCSFR1-Fc-CD40L. In the bottom left panel, the topcurve is CD40L-Fc and the bottom curve hCSFR1-Fc-CD40L.

FIG. 4 shows in vitro cell binding assays which demonstrate the abilityof the human CSF1R(CD115)-Fc-CD40L chimeric protein to bind the CD40receptor expressed by Jurkat cells (a human T cell line). The bindingEC₅₀ was measured to be 77 nM. “ARC” refers to the hCSF1R-Fc-CD40Lchimeric protein.

FIG. 5A to FIG. 5F show the Octet binding affinity of humanCSF1R-Fc-CD40L. On-rates, off-rates, and affinity (KD) were determinedfor human CSF1R-Fc-CD40L to CD40-His (FIG. 5A), commercially availablesingle-sided CD40L-Fc to CD40-His (FIG. 5B), a commercially availableCD40 antibody to CD40-His (FIG. 5C), hCSF1R-Fc-CD40L to CSF1-His (FIG.5D), and commercially available CSF1R-Fc to CSF1-His (FIG. 5E). HumanCSF1R-Fc-CD40L bound CD40 at 4.83 nM and CSF1 at 646 pM (FIG. 5F). Theterm “CSF1R-Fc-CD40L ARC” refers to the CSF1R-Fc-CD40L chimeric protein.In all of FIG. 5A to FIG. 5E, the order of curves, top to bottom is: 100mM test agent, 33 mM test agent, 11 mM test agent, and empty.

FIG. 6 shows characterization by biolayer interferometry (Octet) of therelative binding affinity of human CSF1R-Fc-CD40L to recombinant humanCD40, CSF1, and IL-34. Identical binding was observed for the two CFF1Rligands: CSF1 and IL-34; thus, the curves overlay one another.Therefore, the order of the curves is: CD40-his on top and CSF1-his andIL-34-his on bottom and overlayed.

FIG. 7A and FIG. 7B show characterization by Western blot and functionalELISA binding of the murine CSF1R-Fc-CD40L. FIG. 7A shows Western blotdetection of all three domains of the mCSF1R-Fc-CD40L chimeric proteinunder non-reduced (lane 2), reduced (lane 3), and reduced-FPNGasetreatments (lane 4). The reduced, deglycosylated form of the proteinmigrates at the expected molecular weight of about 105 kDa. FIG. 7Bshows ELISA assays were performed to detect the binding of CSF1R torecombinant CSF1 (left panel), Fc to IgG (center panel), and CD40L torCD40 (right panel) using detection methods outlined in the schematicsabove each graph. CD115 is synonymous with CSF1R. In FIG. 7B, left panelmCD115-Fc-CD40L is the top curve, in the middle and right panelsmCD115-Fc-CD40L is the bottom curve.

FIG. 8 shows in vitro cell binding of murine CSF1R-Fc-CD40L to CHO-K1cells which overexpress murine CD40 (top curve), as compared to aparental CHO-K1 cell line that does not express mCD40 (bottom curve).The binding EC₅₀ was measured at 91.1 nM.

FIG. 9 shows data from an in vitro NF-KB/NIK signaling assay using thehuman CSF1R-Fc-CD40L chimeric protein. U2OS cells from the DiscoverX NIKsignaling assay were cultured with a titration of either acommercially-available single-sided CD40L-Fc, single-sided CSF1R-Fc, oranti-CD40, or the human CSF1R-Fc-CD40L chimeric protein. The relativeluciferase units (RLU) indicate the relative strength of NF-κB/NIKsignaling activated following treatment with the indicated regimens. Thecurves are identified as follows: at 0.01 μg/mL on the X-axis, top tobottom is: CD40L-Fc, hCSF1R-Fc-CD40L, CSF1R-Fc, and anti-CD40.

FIG. 10A and FIG. 10B show in vivo functional readouts of murineCSF1R-Fc-CD40L activity. FIG. 10A shows a CSF1 trap/sink assay.Non-tumor bearing mice were injected with a single dose ofanti-CD115(CSF1R) on day 0. On day 2, mice were either left untreated,or injected with a single dose of the CSF1R-Fc-CD40L chimeric protein.Blood serum was collected on day 2 before injection of the chimericprotein and on day 3 after the chimeric protein treatment. Murine CSF1ELISAs were performed on the serum, and showed that the murineCSF1R-Fc-CD40L chimeric protein binds and eliminates serum CSF1. (FIG.10B shows in vivo IL15Rα Induction. Tumor-bearing mice were treated withtwo doses of 150 μg of mCSF1R-Fc-CD40L ARC on days 5 and 7 after initialtumor inoculation. On day 13, a cohort of mice was sacrificed and theirspleens and lymph nodes were removed and dissociated for flow cytometryanalysis of IL15Rα. Consistent with a known mechanism of CD40L function,mice treated with the CSF1R-Fc-CD40L chimeric protein displayed anincrease in IL15Rα in both tissue compartments. CD115 is synonymous withCSF1R. For the graph of FIG. 10A, the top curve is +αCD115, middle curveis +αCD115 then CD115-Fc-CD40L on day 2, and bottom curve is untreated.For FIG. 10B (top and bottom panels), the left points are control andthe right are CSF1R-Fc-CD40L.

FIG. 11A to FIG. 11C show anti-tumor efficacy of murine CSF1R-Fc-CD40Lin colorectal CT26 tumors. Balb/c mice were inoculated with CT26 tumorson day 0. Following 4 days of tumor growth, when tumors reached adiameter of 4-5 mm, mice were treated with either control antibodies orthe mCSF1R-Fc-CD40L chimeric protein. Treatments were then repeatedagain on day 7. The figure above includes: (FIG. 11A) individual tumorgrowth curves for each treatment group, (FIG. 11A) overall survivalthrough day 60 of the experiment and (FIG. 11A) a table summarizing thetreatment outcomes for each group. CD115 is synonymous with CSF1R. ForFIG. 11B, with reference to day 35, the curves are (top to bottom):CD115-Fc-CD40L (150 μg×2), αCD115, αCD115/CD40, αCD40 (untreated micehave not survived by this point).

FIG. 12A to FIG. 12E show in vivo immunophenotyping in tumor-bearingmice. Tumor-bearing immunophenotyping was also performed for eachtreatment group by analyzing splenocytes, lymph node cells and tumorinfiltrating lymphocytes for mice from each group on day 13 post tumorinoculation. FIG. 12A shows results demonstrating that mice treated withmurine CSF1R-Fc-CD40L had increased frequencies of both CD4+ and CD8+ Tcells in the spleen, but not lymph node or tumor as compared tocontrols. FIG. 12B shows a decrease in the proportion of CD4+CD25+ cellsin the spleen and tumor, which may indicate a decrease inimmunoregulatory T cells. Interestingly, despite a non-significantincrease in the proportion of total CD8+ cells within the tumor (see,FIG. 12C), a significant increase in the proportion of CD8+ T cellsspecific for the AH1 tumor antigen (by tetramer staining) was detected.To determine potential evidence of CD40 receptor activation, inductionof CD19+ cells (FIG. 12D) and IL-15Ra-positive cells (FIG. 12E) wereanalyzed. For all of FIG. 12A to FIG. 12E, the left points are controland the right are CSF1R-Fc-CD40L.

FIG. 13A and FIG. 13B show safety of murine CSF1R-Fc-CD40L versus a CD40agonist antibody. Monotherapy with a CD40 agonist antibody (cloneFGK4.5) or combination therapy with the CD40 agonist antibody and ananti-CD115(CSF1R) antibody (clone AFS98) produced significant diarrheaand weight loss in mice over the course of the experiment. These dataindicate that the CD40 agonist antibody initiated a gut inflammatoryresponse leading to diarrhea and weight loss, which was thensignificantly exacerbated by the combination with CD115 blockade. Micein the antibody combination group lost >25% of their body weight (seeFIG. 13B), had a moribund appearance (FIG. 13A) and in some cases thisinflammatory response was lethal. Importantly, mice treated with themurine CD115-Fc-CD40L chimeric protein (which is another name for themCSF1R-Fc-CD40L chimeric protein) appeared healthy, did not develop anysigns of diarrhea or weight loss, and behaved normally (see photos inleft panel). These data are in accordance with clinical data in humanstreated with CD40 agonist antibodies, and suggest that a beneficialsafety profile of mCD115-Fc-CD40L. CD115 is synonymous with CSF1R. InFIG. 13B, the order of bars is: untreated, αCD115, αCD40, αCD115+αCD40,CD115-Fc-CD40L FP.

FIG. 14 shows four potential configurations of illustrative chimericproteins (PD1-Fc-OX40L).

FIG. 15 shows Western blots of PD1-Fc-OX40L chimeric proteins run onSDS-PAGE under a non-reducing condition, a reducing condition, and areducing condition and following treatment with Peptide-N-Glycosidase F(PNGaseF).

FIG. 16 shows a chromatograph for PD1-Fc-OX40L chimeric proteins run onSize Exclusion Chromatography (SEC).

FIG. 17 shows SDS-PAGE and native (non-SDS) PAGE gels for PD1-Fc-OX40Lchimeric proteins run under a non-reducing condition (“−”) or under areducing condition (“+”).

FIG. 18 shows a native (non-SDS) PAGE gel for PD1-No Fc-OX40L chimericproteins which lack an Fc domain in a linker.

FIG. 19 shows, without wishing to be bound by theory, a model for how ahexamer and concatamers form from chimeric proteins of the presentinvention.

FIG. 20 is a table showing joining linkers and Fc linkers that can becombined into exemplary modular linkers. The exemplary modular linkersshown can be combined with any herein-described Type I and Type IIproteins and/or extracellular domains of a herein described Type I andType II proteins to form a chimeric protein of the present invention.

DETAILED DESCRIPTION

The present invention is based, in part, on the discovery of engineeredchimeric proteins comprising a first domain comprising a portion ofcolony stimulating factor 1 receptor (CSF1R) that is capable of bindinga CSF1R ligand. In embodiments, the chimeric protein further comprises asecond domain comprising a portion of CD40 Ligand (CD40L) that iscapable of binding a CD40L receptor. In embodiments, the first domainand the second domain are connected by a linker. In embodiments, thepresent chimeric protein provides an immune stimulatory signal, forexample, capable of activating macrophages and antigen presenting cells,while providing a localized trap for an inhibitory signal that couldotherwise shift the balance toward immunosuppression (e.g., CSF1 orIL-34). Embodiments of the invention thereby provide for the effectivetreatment of cancers and/or inflammatory diseases.

Chimeric Proteins

In embodiments, the present invention relates to chimeric proteinsengineered to comprise a domain, e.g., the extracellular domain, of theimmune inhibitory receptor colony stimulating factor 1 receptor (CSF1R),also known as macrophage colony-stimulating factor receptor (M-CSFR) andcluster of differentiation 115 (CD115). Thus, throughout thisdisclosure, CSF1R and CD115 are synonymous, when referenced alone and/orwhen referenced in context of a chimeric protein, thus, for example,CSF1R-Fc-CD40L is the same chimeric protein as CD115-Fc-CD40L. CSF1R isa single-pass type I membrane protein which functions as a receptor forcolony stimulating factor 1 (CSF1). CSF1R has also been shown to be areceptor for IL-34. Binding of CSF1R to either CSF1 or IL-34 plays acritical role in the survival, proliferation, and differentiation ofhematopoietic precursor cells, especially mononuclear phagocytes, suchas macrophages and monocytes. Further, CSF1R has been shown to bind toeither CSF1 or IL-34 within the tumor microenvironment. Binding of thereceptor to these ligands induces immune suppression through, interalia, the induction of tumor associated macrophages (TAMs) and myeloidderived suppressor cells (MDSCs).

In embodiments, the present chimeric protein comprises a domain, e.g.,the extracellular domain, of human CSF1R. The human CSF1R comprises theamino acid sequence of SEQ ID NO: 1 (with the amino acid sequence of theextracellular domain comprising amino acids 20 to 517).

In embodiments, the present chimeric protein comprises the extracellulardomain, of human CSF1R, which has the amino acid sequence of SEQ ID NO:2. In embodiments, the present chimeric proteins may comprise theextracellular domain of CSF1R as described herein, or a variant or afunctional fragment thereof. For instance, the chimeric protein maycomprise a sequence of the extracellular domain of CSF1R as providedabove, or a variant or functional fragment thereof having at least about60%, or at least about 61%, or at least about 62%, or at least about63%, or at least about 64%, or at least about 65%, or at least about66%, or at least about 67%, or at least about 68%, or at least about69%, or at least about 70%, or at least about 71%, or at least about72%, or at least about 73%, or at least about 74%, or at least about75%, or at least about 76%, or at least about 77%, or at least about78%, or at least about 79%, or at least about 80%, or at least about81%, or at least about 82%, or at least about 83%, or at least about84%, or at least about 85%, or at least about 86%, or at least about87%, or at least about 88%, or at least about 89%, or at least about90%, or at least about 91%, or at least about 92%, or at least about93%, or at least about 94%, or at least about 95%, or at least about96%, or at least about 97%, or at least about 98%, or at least about 99%sequence identity with the amino acid sequence of the extracellulardomain of CSF1R as described herein.

The structure of CSF1R is described, for example, in W. D. Tap, et al,“Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-CellTumor”, N. Engl. J. Med. 2015 Jul. 30; 373(5):428-37. Derivatives ofCSF1R can be prepared based upon available CSF1R structures.

In embodiments, the present chimeric proteins may comprise a variantextracellular domain of CSF1R in which the signal peptide (e.g., asprovided in SEQ ID NO: 1) is replaced with an alternative signalpeptide. In embodiments, the present chimeric protein may comprise avariant extracellular domain of CSF1R which is expressed from a cDNAthat has been codon-optimized for expression in protein producing cellssuch as Chinese Hamster Ovary (CHO) or human embryonic kidney (HEK)cells.

In embodiments, an extracellular domain of CSF1R refers to a portion ofthe protein which is capable of interacting with the extracellularenvironment. In embodiments, the extracellular domain of CSF1R is theentire amino acid sequence of the protein which is external of a cell orthe cell membrane. In embodiments, the extracellular domain of CSF1R isa portion of an amino acid sequence of the protein which is external ofa cell or the cell membrane and is needed for signal transduction and/orligand binding as may be assayed using methods known in the art (e.g.,in vitro ligand binding and/or cellular activation assays).

In embodiments, the extracellular domain of CSF1R refers to a portion ofthe protein which is capable for binding to colony stimulating factor 1(CSF1). In embodiments, the chimeric protein binds to human CSF1 with aK_(D) of less than about 1 pM, about 900 nM, about 800 nM, about 700 nM,about 600 nM, about 500 nM, about 400 nM, about 300 nM, about 200 nM,about 150 nM, about 130 nM, about 100 nM, about 90 nM, about 80 nM,about 70 nM, about 60 nM, about 55 nM, about 50 nM, about 45 nM, about40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM, about 15 nM,about 10 nM, or about 5 nM, or about 1 nM (as measured, for example, bysurface plasmon resonance or biolayer interferometry). In embodiments,the chimeric protein binds to human CSF1 with a K_(D) of less than about1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM, about 500pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM,about 80 pM, about 70 pM, about 60 pM about 55 pM about 50 pM about 45pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM, about 20 pM,about 15 pM, or about 10 pM, or about 1 pM (as measured, for example, bysurface plasmon resonance or biolayer interferometry).

In embodiments, the extracellular domain of CSF1R refers to a portion ofthe protein which is capable for binding to IL-34. In embodiments, thechimeric protein binds to human IL-34 with a K_(D) of less than about 1μM, about 900 nM, about 800 nM, about 700 nM, about 600 nM, about 500nM, about 400 nM, about 300 nM, about 200 nM, about 100 nM, about 90 nM,about 80 nM, about 70 nM, about 60 nM, about 55 nM, about 50 nM, about45 nM, about 40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM,about 15 nM, about 10 nM, or about 5 nM, or about 1 nM (as measured, forexample, by surface plasmon resonance or biolayer interferometry). Inembodiments, the chimeric protein binds to IL-34 with a K_(D) of lessthan about 1 nM, about 900 pM, about 800 pM, about 700 pM, about 600 pM,about 500 pM, about 400 pM, about 300 pM, about 200 pM, about 100 pM,about 90 pM, about 80 pM, about 70 pM, about 60 pM about 55 pM about 50pM about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25 pM,about 20 pM, about 15 pM, or about 10 pM, or about 1 pM (as measured,for example, by surface plasmon resonance or biolayer interferometry).In embodiments, the chimeric protein binds to human CSF1 with a K_(D) offrom about 100 pM to about 600 pM.

The present chimeric protein further comprises a domain, e.g., theextracellular domain, of the immune stimulatory molecule CD40 ligand(CD40L, also known as CD154). CD40L is a type II transmembrane proteinbelonging to the Tumor Necrosis Factor (TNF) superfamily. CD40L binds tothe CD40 receptor on macrophages and antigen-presenting cells (APC)including antigen-presenting B cells, which leads to many effectsdepending on the target cell type. CD40L has also been shown to bind theintegrins α5β1 and αllbβ3. CD40L acts as a costimulatory molecule and isparticularly important on a subset of T cells called T follicular helpercells (TFH cells). On TFH cells, CD40L promotes B cell maturation andfunction by engaging CD40 on the B cell surface and thereforefacilitating cell-cell communication.

In embodiments, the present chimeric protein comprises a domain, e.g.,the extracellular domain, of human CD40L. The human CD40L comprises theamino acid sequence of SEQ ID NO: 3 (with the amino acid sequence of theextracellular domain comprising amino acids 47 to 261). In embodiments,the present chimeric protein comprises the extracellular domain of humanCD40L which has the amino acid sequence of SEQ ID NO: 4. In embodiments,the present chimeric proteins may comprise the extracellular domain ofCD40L as described herein, or a variant or functional fragment thereof.For instance, the chimeric protein may comprise a sequence of theextracellular domain of CD40L as provided above, or a variant orfunctional fragment thereof having at least about 60%, or at least about61%, or at least about 62%, or at least about 63%, or at least about64%, or at least about 65%, or at least about 66%, or at least about67%, or at least about 68%, or at least about 69%, or at least about70%, or at least about 71%, or at least about 72%, or at least about73%, or at least about 74%, or at least about 75%, or at least about76%, or at least about 77%, or at least about 78%, or at least about79%, or at least about 80%, or at least about 81%, or at least about82%, or at least about 83%, or at least about 84%, or at least about85%, or at least about 86%, or at least about 87%, or at least about88%, or at least about 89%, or at least about 90%, or at least about91%, or at least about 92%, or at least about 93%, or at least about94%, or at least about 95%, or at least about 96%, or at least about97%, or at least about 98%, or at least about 99%) sequence identitywith the amino acid sequence of the extracellular domain of CD40L asdescribed herein.

CD40L derivatives can be constructed from available structural data,including that described by Oganesyan V., et al., “Fibronectin type IIIdomains engineered to bind CD40L: cloning, expression, purification,crystallization and preliminary X-ray diffraction analysis of twocomplexes”, Acta Crystallogr Sect F Struct Biol Cyst Commun. 2013September; 69(Pt 9):1045-8.

In embodiments, the present chimeric proteins may comprise a variantextracellular domain of CD40L in which the signal peptide (e.g., asprovided in SEQ ID NO: 3) is replaced with an alternative signalpeptide. In embodiments, the present chimeric protein may comprise avariant extracellular domain of CD40L which is expressed from a cDNAthat has been codon-optimized for expression in protein producing cellssuch as Chinese Hamster Ovary (CHO) or HEK cells.

In embodiments, the extracellular domain of CD40L refers to a portion ofprotein which is capable of interacting with the extracellularenvironment. In embodiments, the extracellular domain of CD40L is theentire amino acid sequence of the protein which is external of a cell orthe cell membrane. In embodiments, the extracellular domain of CD40L isa portion of an amino acid sequence of the protein which is external ofa cell or the cell membrane and is needed for signal transduction and/orligand binding as may be assayed using methods know in the art.

In embodiments, the extracellular domain of CD40L refers to a portion ofthe protein which is capable for binding to the CD40 receptor. Similarto other TNF superfamily members, membrane-bound CD40L exists as ahomotrimer. CD40L binds to CD40, a member of the TNF receptorsuperfamily that is expressed predominantly on antigen presenting cells,including dendritic cells (DCs), B cells and macrophages. The CD40L/CD40interactions exert profound effects on dendritic cells, B cells, andendothelial cells, among many cells of the hematopoietic andnon-hematopoietic compartments. For example, CD40 signaling induces DCsto mature and effectively trigger T-cell activation and differentiation.CD40 signaling of B cells promotes germinal center (GC) formation,immunoglobulin (Ig) isotype switching, somatic hypermutation (SHM) ofthe Ig to enhance affinity for antigen, and the formation of long-livedplasma cells and memory B cells. CD40 signaling is also critical forimmune cell survival.

In embodiments, the chimeric protein of the invention binds to humanCD40 with a K_(D) of less than about 1 μM, about 900 nM, about 800 nM,about 700 nM, about 600 nM, about 550 nM, about 530 nM, about 500 nM,about 400 nM, about 300 nM, about 200 nM, about 100 nM, about 90 nM,about 80 nM, about 70 nM, about 60 nM, about 55 nM, about 50 nM, about45 nM, about 40 nM, about 35 nM, about 30 nM, about 25 nM, about 20 nM,about 15 nM, about 10 nM, or about 5 nM, or about 1 nM (as measured, forexample, by surface plasmon resonance or biolayer interferometry). Inembodiments, the chimeric protein binds to human CD40 with a K_(D) ofless than about 1 nM, about 900 pM, about 800 pM, about 700 pM, about600 pM, about 500 pM, about 400 pM, about 300 pM, about 200 pM, about100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM about 55 pMabout 50 pM about 45 pM, about 40 pM, about 35 pM, about 30 pM, about 25pM, about 20 pM, about 15 pM, or about 10 pM, or about 1 pM (asmeasured, for example, by surface plasmon resonance or biolayerinterferometry). In embodiments, the chimeric protein binds to humanCD40 with a K_(D) of from about 300 pM to about 700 pM.

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CSF1R (SEQ ID NO: 2).

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CD40L (SEQ ID NO: 4).

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of OX40L (SEQ ID NO: 7).

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CSF1R (SEQ ID NO: 2) and the extracellulardomain of CD40L (SEQ ID NO: 4).

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CSF1R (SEQ ID NO: 2) and the extracellulardomain of OX40L (SEQ ID NO: 7).

In embodiments, the chimeric protein of the present invention comprisesthe hinge-CH2-CH3 domain from a human IgG4 antibody sequence (SEQ ID NO:25, SEQ ID NO: 26, or SEQ ID NO: 27).

In embodiments, a chimeric protein comprises a modular linker as shownin FIG. 20.

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CSF1R and the extracellular domain of CD40L,using the hinge-CH2-CH3 domain from a human IgG4 antibody sequence as alinker (this CSF1R-Fc-CD40L chimera is SEQ ID NO: 5).

In embodiments, the chimeric protein of the present invention comprisesan extracellular domain of CSF1R and the extracellular domain of OX40L,using the hinge-CH2-CH3 domain from a human IgG4 antibody sequence as alinker (this CSF1R-Fc-OX40L chimera is SEQ ID NO: 8).

In embodiments, the chimeric protein of the present invention comprisesSEQ ID NO: 5, i.e., monomeric CSF1R-Fc-CD40L chimeric protein(SL-115154), or a variant or functional fragment thereof.

In embodiments, the chimeric protein may have at least about 60%, or atleast about 61%, or at least about 62%, or at least about 63%, or atleast about 64%, or at least about 65%, or at least about 66%, or atleast about 67%, or at least about 68%, or at least about 69%, or atleast about 70%, or at least about 71%, or at least about 72%, or atleast about 73%, or at least about 74%, or at least about 75%, or atleast about 76%, or at least about 77%, or at least about 78%, or atleast about 79%, or at least about 80%, or at least about 81%, or atleast about 82%, or at least about 83%, or at least about 84%, or atleast about 85%, or at least about 86%, or at least about 87%, or atleast about 88%, or at least about 89%, or at least about 90%, or atleast about 91%, or at least about 92%, or at least about 93%, or atleast about 94%, or at least about 95%, or at least about 96%, or atleast about 97%, or at least about 98%, or at least about 99% sequenceidentity with the amino acid sequence of any one of SEQ ID NO: 5 or 8.

In embodiments, the chimeric proteins of the invention may comprise asequence which has one or more amino acid mutations with respect to anyone of the sequences disclosed herein. In embodiments, the chimericprotein comprises a sequence that has about 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95,or 100 or more amino acid mutations with respect to any one of the aminoacid sequences of chimeric proteins disclosed herein.

In embodiments, the one or more amino acid mutations may beindependently selected from substitutions, insertions, deletions, andtruncations.

In embodiments, the amino acid mutations are amino acid substitutions,and may include conservative and/or non-conservative substitutions.

“Conservative substitutions” may be made, for instance, on the basis ofsimilarity in polarity, charge, size, solubility, hydrophobicity,hydrophilicity, and/or the amphipathic nature of the amino acid residuesinvolved. The 20 naturally occurring amino acids can be grouped into thefollowing six standard amino acid groups: (1) hydrophobic: Met, Ala,Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr; Asn, Gln; (3)acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that influencechain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe.

As used herein, “conservative substitutions” are defined as exchanges ofan amino acid with another amino acid listed within the same group ofthe six standard amino acid groups shown above. For example, theexchange of Asp by Glu retains one negative charge in the so-modifiedpolypeptide. In addition, glycine and proline may be substituted for oneanother based on their ability to disrupt α-helices.

As used herein, “non-conservative substitutions” are defined asexchanges of an amino acid with another amino acid listed in a differentgroup of the six standard amino acid groups (1) to (6) shown above.

In embodiments, the substitutions may also include non-classical aminoacids (e.g., selenocysteine, pyrrolysine, N-formylmethionine β-alanine,GABA and δ-Aminolevulinic acid, 4-aminobenzoic acid (PABA), D-isomers ofthe common amino acids, 2,4-diaminobutyric acid, α-amino isobutyricacid, 4-aminobutyric acid, Abu, 2-amino butyric acid, γ-Abu, ε-Ahx,6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionicacid, ornithine, norleucine, norvaline, hydroxyproline, sarcosme,citrulline, homocitrulline, cysteic acid, t-butylglycine,t-butylalanine, phenylglycine, cyclohexylalanine, β-alanine,fluoro-amino acids, designer amino acids such as β methyl amino acids, Cα-methyl amino acids, N α-methyl amino acids, and amino acid analogs ingeneral).

Mutations may also be made to the nucleotide sequences of the chimericproteins by reference to the genetic code, including taking into accountcodon degeneracy.

In embodiments, the chimeric protein comprises a linker. In embodiments,the linker comprising at least one cysteine residue capable of forming adisulfide bond. As described elsewhere herein, such at least onecysteine residue capable of forming a disulfide bond is, without wishingto be bound by theory, responsible for maintain a proper multimericstate of the chimeric protein and allowing for efficient production.

In embodiments, the chimeric protein of the present invention comprises(a) a first domain comprising a portion of colony stimulating factor 1receptor (CSF1R), e.g., the extracellular domain of CSF1R, that iscapable of binding a CSF1R ligand; (b) a second domain comprising aportion of CD40 Ligand (CD40L), e.g., the extracellular domain of CD40L,that is capable of binding a CD40L receptor; and (c) a linker linkingthe first domain and the second domain.

In embodiments, chimeric protein is a recombinant fusion protein, e.g.,a single polypeptide having the extracellular domains described herein(and, optionally a linker). For example, in embodiments, the chimericprotein is translated as a single unit in a cell. In embodiments, achimeric protein refers to a recombinant protein of multiplepolypeptides, e.g. multiple extracellular domains described herein, thatare linked to yield a single unit, e.g. in vitro (e.g. with one or moresynthetic linkers described herein). In embodiments, the chimericprotein is chemically synthesized as one polypeptide or each domain maybe chemically synthesized separately and then combined. In embodiments,a portion of the chimeric protein is translated and a portion ischemically synthesized.

In embodiments, the present chimeric proteins may be variants describedherein, for instance, the present chimeric proteins may have a sequencehaving at least about 60%, or at least about 61%, or at least about 62%,or at least about 63%, or at least about 64%, or at least about 65%, orat least about 66%, or at least about 67%, or at least about 68%, or atleast about 69%, or at least about 70%, or at least about 71%, or atleast about 72%, or at least about 73%, or at least about 74%, or atleast about 75%, or at least about 76%, or at least about 77%, or atleast about 78%, or at least about 79%, or at least about 80%, or atleast about 81%, or at least about 82%, or at least about 83%, or atleast about 84%, or at least about 85%, or at least about 86%, or atleast about 87%, or at least about 88%, or at least about 89%, or atleast about 90%, or at least about 91%, or at least about 92%, or atleast about 93%, or at least about 94%, or at least about 95%, or atleast about 96%, or at least about 97%, or at least about 98%, or atleast about 99%) sequence identity with the amino acid sequence of thepresent chimeric proteins, e.g. one or more of SEQ IDs Nos 5 and 8.

In embodiments, the chimeric protein comprises a linker. In embodiments,the linker may be derived from naturally-occurring multi-domain proteinsor are empirical linkers as described, for example, in Chichili et al.,(2013), Protein Sci. 22(2):153-167, Chen et al., (2013), Adv Drug DelivRev. 65(10):1357-1369, the entire contents of which are herebyincorporated by reference. In embodiments, the linker may be designedusing linker designing databases and computer programs such as thosedescribed in Chen et al, (2013), Adv Drug Deliv Rev. 65(10):1357-1369and Crasto et. al., (2000), Protein Eng. 13(5):309-312, the entirecontents of which are hereby incorporated by reference.

In embodiments, the linker is a synthetic linker such as PEG.

In embodiments, the linker comprises a polypeptide. In embodiments, thepolypeptide is less than about 500 amino acids long, about 450 aminoacids long, about 400 amino acids long, about 350 amino acids long,about 300 amino acids long, about 250 amino acids long, about 200 aminoacids long, about 150 amino acids long, or about 100 amino acids long.For example, the linker may be less than about 100, about 95, about 90,about 85, about 80, about 75, about 70, about 65, about 60, about 55,about 50, about 45, about 40, about 35, about 30, about 25, about 20,about 19, about 18, about 17, about 16, about 15, about 14, about 13,about 12, about 11, about 10, about 9, about 8, about 7, about 6, about5, about 4, about 3, or about 2 amino acids long. In embodiments, thelinker is flexible. In an embodiment, the linker is rigid.

In embodiments, the linker is substantially comprised of glycine andserine residues (e.g., about 30%, or about 40%, or about 50%, or about60%, or about 70%, or about 80%, or about 90%, or about 95%, or about97%, or about 98%, or about 99%, or about 100% glycines and serines).

In embodiments, the linker comprises a hinge region of an antibody(e.g., of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g., IgG1,IgG2, IgG3, and IgG4, and IgA1 and IgA2)). The hinge region, found inIgG, IgA, IgD, and IgE class antibodies, acts as a flexible spacer,allowing the Fab portion to move freely in space. In contrast to theconstant regions, the hinge domains are structurally diverse, varying inboth sequence and length among immunoglobulin classes and subclasses.For example, the length and flexibility of the hinge region varies amongthe IgG subclasses. The hinge region of IgG1 encompasses amino acids216-231 and, because it is freely flexible, the Fab fragments can rotateabout their axes of symmetry and move within a sphere centered at thefirst of two inter-heavy chain disulfide bridges. IgG2 has a shorterhinge than IgG1, with 12 amino acid residues and four disulfide bridges.The hinge region of IgG2 lacks a glycine residue, is relatively short,and contains a rigid poly-proline double helix, stabilized by extrainter-heavy chain disulfide bridges. These properties restrict theflexibility of the IgG2 molecule. IgG3 differs from the other subclassesby its unique extended hinge region (about four times as long as theIgG1 hinge), containing 62 amino acids (including 21 prolines and 11cysteines), forming an inflexible poly-proline double helix. In IgG3,the Fab fragments are relatively far away from the Fc fragment, givingthe molecule a greater flexibility. The elongated hinge in IgG3 is alsoresponsible for its higher molecular weight compared to the othersubclasses. The hinge region of IgG4 is shorter than that of IgG1 andits flexibility is intermediate between that of IgG1 and IgG2. Theflexibility of the hinge regions reportedly decreases in the orderIgG3>IgG1>IgG4>IgG2. In embodiments, the linker may be derived fromhuman IgG4 and contain one or more mutations to enhance dimerization(including S228P) or FcRn binding.

According to crystallographic studies, the immunoglobulin hinge regioncan be further subdivided functionally into three regions: the upperhinge region, the core region, and the lower hinge region. See Shin etal, 1992 Immunological Reviews 130:87. The upper hinge region includesamino acids from the carboxyl end of C_(H1) to the first residue in thehinge that restricts motion, generally the first cysteine residue thatforms an interchain disulfide bond between the two heavy chains. Thelength of the upper hinge region correlates with the segmentalflexibility of the antibody. The core hinge region contains theinter-heavy chain disulfide bridges, and the lower hinge region joinsthe amino terminal end of the C_(H2) domain and includes residues inC_(H2). Id. The core hinge region of wild-type human IgG1 contains thesequence CPPC (SEQ ID NO: 48) which, when dimerized by disulfide bondformation, results in a cyclic octapeptide believed to act as a pivot,thus conferring flexibility. In embodiments, the present linkercomprises, one, or two, or three of the upper hinge region, the coreregion, and the lower hinge region of any antibody (e.g., of IgG, IgA,IgD, and IgE, inclusive of subclasses (e.g., IgG1, IgG2, IgG3, and IgG4,and IgA1 and IgA2)). The hinge region may also contain one or moreglycosylation sites, which include a number of structurally distincttypes of sites for carbohydrate attachment. For example, IgA1 containsfive glycosylation sites within a 17-amino-acid segment of the hingeregion, conferring resistance of the hinge region polypeptide tointestinal proteases, considered an advantageous property for asecretory immunoglobulin. In embodiments, the linker of the presentinvention comprises one or more glycosylation sites.

In embodiments, the linker comprises an Fc domain of an antibody (e.g.,of IgG, IgA, IgD, and IgE, inclusive of subclasses (e.g., IgG1, IgG2,IgG3, and IgG4, and IgA1 and IgA2)). In embodiments, the linkercomprises a hinge-CH2-CH3 Fc domain derived from a human IgG4 antibody.In embodiments, the linker comprises a hinge-CH2-CH3 Fc domain derivedfrom a human IgG1 antibody. In embodiments, the Fc domain exhibitsincreased affinity for and enhanced binding to the neonatal Fc receptor(FcRn). In embodiments, the Fc domain includes one or more mutationsthat increases the affinity and enhances binding to FcRn. Withoutwishing to be bound by theory, it is believed that increased affinityand enhanced binding to FcRn increases the in vivo half-life of thepresent chimeric proteins.

In embodiments, the Fc domain in a linker contains one or more aminoacid substitutions at amino acid residue 250, 252, 254, 256, 308, 309,311, 416, 428, 433 or 434 (in accordance with Kabat numbering, as in asin Kabat, et al., Sequences of Proteins of Immunological Interest, 5thEd. Public Health Service, National Institutes of Health, Bethesda, Md.(1991) expressly incorporated herein by reference), or equivalentsthereof. In embodiments, the amino acid substitution at amino acidresidue 250 is a substitution with glutamine. In embodiments, the aminoacid substitution at amino acid residue 252 is a substitution withtyrosine, phenylalanine, tryptophan or threonine. In embodiments, theamino acid substitution at amino acid residue 254 is a substitution withthreonine. In embodiments, the amino acid substitution at amino acidresidue 256 is a substitution with serine, arginine, glutamine, glutamicacid, aspartic acid, or threonine. In embodiments, the amino acidsubstitution at amino acid residue 308 is a substitution with threonine.In embodiments, the amino acid substitution at amino acid residue 309 isa substitution with proline. In embodiments, the amino acid substitutionat amino acid residue 311 is a substitution with serine. In embodiments,the amino acid substitution at amino acid residue 385 is a substitutionwith arginine, aspartic acid, serine, threonine, histidine, lysine,alanine or glycine. In embodiments, the amino acid substitution at aminoacid residue 386 is a substitution with threonine, proline, asparticacid, serine, lysine, arginine, isoleucine, or methionine. Inembodiments, the amino acid substitution at amino acid residue 387 is asubstitution with arginine, proline, histidine, serine, threonine, oralanine. In embodiments, the amino acid substitution at amino acidresidue 389 is a substitution with proline, serine or asparagine. Inembodiments, the amino acid substitution at amino acid residue 416 is asubstitution with serine. In embodiments, the amino acid substitution atamino acid residue 428 is a substitution with leucine. In embodiments,the amino acid substitution at amino acid residue 433 is a substitutionwith arginine, serine, isoleucine, proline, or glutamine. Inembodiments, the amino acid substitution at amino acid residue 434 is asubstitution with histidine, phenylalanine, or tyrosine.

In embodiments, the Fc domain in a linker (e.g., comprising an IgGconstant region) comprises one or more mutations such as substitutionsat amino acid residue 252, 254, 256, 433, 434, or 436 (in accordancewith Kabat numbering, as in as in Kabat, et al., Sequences of Proteinsof Immunological Interest, 5th Ed. Public Health Service, NationalInstitutes of Health, Bethesda, Md. (1991) expressly incorporated hereinby reference). In embodiments, the IgG constant region includes a tripleM252Y/S254T/T256E mutation or YTE mutation. In an embodiment, the IgGconstant region includes a triple H433K/N434F/Y436H mutation or KFHmutation. In embodiments, the IgG constant region includes an YTE andKFH mutation in combination.

In embodiments, the modified humanized antibodies of the inventioncomprise an IgG constant region that contains one or more mutations atamino acid residues 250, 253, 307, 310, 380, 428, 433, 434, and 435 (inaccordance with Kabat numbering, as in as in Kabat, et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991) expresslyincorporated herein by reference). Illustrative mutations include T250Q,M428L, 1307A, E380A, 1253A, H310A, M428L, H433K, N434A, N434F, N434S,and H435A. In embodiments, the IgG constant region comprises aM428L/N434S mutation or LS mutation. In an embodiment, the IgG constantregion comprises a T250Q/M428L mutation or QL mutation. In anembodiment, the IgG constant region comprises an N434A mutation. In anembodiment, the IgG constant region comprises a T307A/E380A/N434Amutation or AAA mutation. In an embodiment, the IgG constant regioncomprises an 1253A/H310A/H435A mutation or IHH mutation. In anembodiment, the IgG constant region comprises a H433K/N434F mutation. Inan embodiment, the IgG constant region comprises a M252Y/S254T/T256E anda H433K/N434F mutation in combination.

Additional exemplary mutations in the IgG constant region are described,for example, in Robbie, et al., Antimicrobial Agents and Chemotherapy(2013), 57(12):6147-6153, Dall'Acqua et al., JBC (2006),281(33):23514-24, Dall'Acqua et al, Journal of Immunology (2002),169:5171-80, Ko et al. Nature (2014) 514:642-645, Grevys et al. Journalof Immunology. (2015), 194(11):5497-508, and U.S. Pat. No. 7,083,784,the entire contents of which are hereby incorporated by reference.

In embodiments, the Fc domain in a linker has the amino acid sequence ofSEQ ID NO: 25 (see the below table), or at least 90%, or 93%, or 95%, or97%, or 98%, or 99% identity thereto. In embodiments, mutations are madeto SEQ ID NO: 25 to increase stability and/or half-life. For instance,in embodiments, the Fc domain in a linker comprises the amino acidsequence of SEQ ID NO: 26 (see the below table), or at least 90%, or93%, or 95%, or 97%, or 98%, or 99% identity thereto. An illustrative Fcstabilizing mutant is S228P. Illustrative Fc half-life extending mutantsare T250Q, M428L, V308T, L309P, and Q311S and the present linkers maycomprise 1, or 2, or 3, or 4, or 5 of these mutants. For instance, inembodiments, the Fc domain in a linker comprises the amino acid sequenceof SEQ ID NO: 27 (see the below table), or at least 90%, or 93%, or 95%,or 97%, or 98%, or 99% identity thereto.

Further, one or more joining linkers may be employed to connect an Fcdomain in a linker (e.g., one of SEQ ID NO: 25, SEQ ID NO: 26, SEQ IDNO: 27, or at least 90%, or 93%, or 95%, or 97%, or 98%, or 99% identitythereto) and the extracellular domains. For example, any one of SEQ IDNO: 28, SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQID NO: 33, or variants thereof may connect an extracellular domain (ECD)as described herein and an Fc domain in a linker as described herein.Optionally, any one of SEQ ID NOs: 28 to 74, or variants thereof arelocated between an extracellular domain as described herein and an Fcdomain as described herein. In embodiments, a chimeric protein comprisesone joining linker preceding an Fc domain and a second joining linkerfollowing the Fc domain; thus, a chimeric protein may comprise thefollowing structure:

-   -   ECD 1 (e.g., CSF1R)-Joining Linker 1-Fc Domain-Joining Linker        2-ECD 2 (e.g., CD40L).

In embodiments, the first and second joining linkers may be different orthey may be the same.

In embodiments, the first and second joining linkers may be selectedfrom the amino acid sequences of SEQ ID NOs: 25 to 74 and are providedin Table 1 below:

TABLE 1 Illustrative linkers (Fc domain linkers and joining linkers)SEQ ID NO. Sequence 25APEFLGGPSVFLFPPKPKDILMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK 26APEFLGGPSVFLFPPKPKDQLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTTPHSDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSSWQEGNVFSCSVLHEALHNHYTQKSLSLSLGK 27APEFLGGPSVFLFPPKPKDQLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLSGKEYKCKVSSKGLPSSIEKTISNATGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVLHEALHNHYTQKSLSLSLGK 28 SKYGPPCPSCP 29 SKYGPPCPPCP 30SKYGPP 31 IEGRMD 32 GGGVPRDCG 33 IEGRMDGGGGAGGGG 34 GGGSGGGS 35GGGSGGGGSGGG 36 EGKSSGSGSESKST 37 GGSG 38 GGSGGGSGGGSG 39EAAAKEAAAKEAAAK 40 EAAAREAAAREAAAREAAAR 41 GGGGSGGGGSGGGGSAS 42GGGGAGGGG 43 GS or GGS or LE 44 GSGSGS 45 GSGSGSGSGS 46 GGGGSAS 47APAPAPAPAPAPAPAPAPAP 48 CPPC 49 GGGGS 50 GGGGSGGGGS 51 GGGGSGGGGSGGGGS52 GGGGSGGGGSGGGGSGGGGS 53 GGGGSGGGGSGGGGSGGGGSGGGGS 54GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 55 GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 56GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 57 GGSGGSGGGGSGGGGS 58 GGGGGGGG59 GGGGGG 60 EAAAK 61 EAAAKEAAAK 62 EAAAKEAAAKEAAAK 63 AEAAAKEAAAKA 64AEAAAKEAAAKEAAAKA 65 AEAAAKEAAAKEAAAKEAAAKA 66AEAAAKEAAAKEAAAKEAAAKEAAAKA 67AEAAAKEAAAKEAAAKEAAAKALEAEAAAKEAAAKEAAAKEAAAKA 68 PAPAP 69KESGSVSSEQLAQFRSLD 70 GSAGSAAGSGEF 71 GGGSE 72 GSESG 73 GSEGS 74GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS

In embodiments, the joining linker substantially comprises glycine andserine residues (e.g., about 30%, or about 40%, or about 50%, or about60%, or about 70%, or about 80%, or about 90%, or about 95%, or about97%, or about 98%, or about 99%, or about 100% glycines and serines).For example, in embodiments, the joining linker is (Gly₄Ser)_(n), wheren is from about 1 to about 8, e.g., 1, 2, 3, 4, 5, 6, 7, or 8 (SEQ IDNO: 49 to SEQ ID NO: 56, respectively). In embodiments, the joininglinker sequence is GGSGGSGGGGSGGGGS (SEQ ID NO: 57). Additionalillustrative joining linkers include, but are not limited to, linkershaving the sequence LE, (Gly)₈ (SEQ ID NO: 58), (Gly)₆ (SEQ ID NO: 59),(EAAAK)_(n) (n=1-3) (SEQ ID NO: 60-SEQ ID NO: 62), A(EAAAK)_(n)A (n=2-5)(SEQ ID NO: 63-SEQ ID NO: 66), A(EAAAK)₄ALEA(EAAAK)₄A (SEQ ID NO: 67),PAPAP (SEQ ID NO: 68), KESGSVSSEQLAQFRSLD (SEQ ID NO: 69), GSAGSAAGSGEF(SEQ ID NO: 70), and (XP)_(n), with X designating any amino acid, e.g.,Ala, Lys, or Glu. In embodiments, the joining linker is GGS.

In embodiments, the joining linker is one or more of GGGSE (SEQ ID NO:71), GSESG (SEQ ID NO: 72), GSEGS (SEQ ID NO: 73),GEGGSGEGSSGEGSSSEGGGSEGGGSEGGGSEGGS (SEQ ID NO: 74), and a joininglinker of randomly placed G, S, and E every 4 amino acid intervals.

In embodiments, a chimeric protein comprises a modular linker as shownin FIG. 20.

In embodiments, the linker may be functional. For example, withoutlimitation, the linker may function to improve the folding and/orstability, improve the expression, improve the pharmacokinetics, and/orimprove the bioactivity of the present chimeric protein. In anotherexample, the linker may function to target the chimeric protein to aparticular cell type or location.

In embodiments, the chimeric protein exhibits enhanced stability andprotein half-life. In embodiments, the chimeric protein binds to FcRnwith high affinity. In embodiments, the chimeric protein may bind toFcRn with a K_(D) of about 1 nM to about 80 nM. For example, thechimeric protein may bind to FcRn with a K_(D) of about 1 nM, about 2nM, about 3 nM, about 4 nM, about 5 nM, about 6 nM, about 7 nM, about 8nM, about 9 nM, about 10 nM, about 15 nM, about 20 nM, about 25 nM,about 30 nM, about 35 nM, about 40 nM, about 45 nM, about 50 nM, about55 nM, about 60 nM, about 65 nM, about 70 nM, about 71 nM, about 72 nM,about 73 nM, about 74 nM, about 75 nM, about 76 nM, about 77 nM, about78 nM, about 79 nM, or about 80 nM. In embodiments, the chimeric proteinmay bind to FcRn with a K_(D) of about 9 nM. In embodiments, thechimeric protein does not substantially bind to other Fc receptors(i.e., other than FcRn) with effector function.

In embodiments, a chimeric protein having the formula ECD 1-JoiningLinker 1-Fc Domain-Joining Linker 2-ECD 2, in which ECD 1 is CSF1R andECD 2 is CD40L may be referred to in the present disclosure asCSF1R-Fc-CD40L. In embodiments, the chimeric protein lacks one or bothjoining linkers; such a chimeric protein may also be referred to in thepresent disclosure as CSF1R-Fc-CD40L.

In embodiments, a chimeric protein is a fusion protein having theformula N terminus-(a)-(b)-(c)-C terminus, in which (a) is CSF1R, (b) isa linker comprising at least a portion of a Fc domain, and (c) is CD40Lmay be referred to in the present disclosure as CSF1R-Fc-CD40L.

In embodiments, a chimeric protein is optimized for/directed to murineligands/receptors; an example of such a chimeric protein is murineCSF1R-Fc-CD40L, which is also referred herein as mCSF1R-Fc-CD40L.

In embodiments, a chimeric protein is optimized for/directed to humanligands/receptors; an example of such a chimeric protein is humanCSF1R-Fc-CD40L, which is also referred herein as hCSF1R-Fc-CD40L.

These chimeric proteins may lack one or both of the joining linkers.Exemplary Joining Linker 1s, Fc Domains, and Joining Linker 2s aredescribed above in Table 1; modular linkers useful for forming chimericproteins and comprising specific Joining Linker 1s, Fc Domains, andJoining Linker 2s are shown in FIG. 20. In embodiments, the presentchimeric protein is engineered to target the CSF1R/CSF1 immuneinhibitory signaling pathway. In embodiment, the chimeric protein isengineered to disrupt, block, reduce, and/or inhibit the transmission ofan immune inhibitory signal mediated by binding of CSF1 to CSF1R. Inembodiments, an immune inhibitory signal refers to a signal thatdiminishes or eliminates an immune response. For example, in the contextof oncology, such signals may diminish or eliminate antitumor immunity.Under normal physiological conditions, inhibitory signals are useful inthe maintenance of self-tolerance (e.g., prevention of autoimmunity) andalso to protect tissues from damage when the immune system is respondingto pathogenic infection. For instance, without limitation, an immuneinhibitory signal may be identified by detecting an increase in cellularproliferation, cytokine production, cell killing activity or phagocyticactivity when such an inhibitory signal is blocked.

In embodiments, the present chimeric protein disrupts, blocks, reduces,and/or inhibits the transmission of an immune inhibitory signal mediatedby the binding of CSF1 or IL-34 to CSF1R. In embodiments, the chimericprotein binds to and sequesters CSF1 or IL-34, and thereby disrupts,blocks, reduces, and/or inhibits the inhibitory signal transmission toan immune cell (e.g., a tumor-associated macrophage, antigen presentingcell, myeloid cell, or a T cell).

In embodiments, the present chimeric proteins are capable of, or finduse in methods comprising, inhibiting or reducing the binding of theimmune inhibitory receptor/ligand pair: CSF1R/CSF1 or CSF1R/IL-34. Inembodiments, the present chimeric protein blocks, reduces, and/orinhibits CSF1R activation, for example, by reducing the binding of CSF1Ron immune cells with CSF1 or IL-34.

In embodiments, the present chimeric protein targets an immunestimulatory signal mediated by the binding of CD40L to CD40. Inembodiment, the chimeric protein is engineered to enhance, increase,and/or stimulate the transmission of an immune stimulatory signalmediated by binding of CD40L to CD40. In embodiments, an immunestimulatory signal refers to a signal that enhances an immune response.For example, in the context of oncology, such signals may enhanceantitumor immunity. For instance, without limitation, immune stimulatorysignal may be identified by directly stimulating proliferation, cytokineproduction, killing activity or phagocytic activity of leukocytes,including subsets of T cells.

In embodiments, the present chimeric protein enhances, increases, and/orstimulates the transmission of an immune stimulatory signal mediated bythe binding of CD40L to CD40. In embodiments, the present chimericprotein comprising the extracellular domain of CD40L acts on an immunecell (e.g., a dendritic cell, a B cell, a macrophage, an antigenpresenting cell, or a T cell) that expresses CD40 and enhances,increases, and/or stimulates stimulatory signal transmission to theimmune cell (e.g., a dendritic cell, a B cell, a macrophage, and a Tcell).

In embodiments, the present chimeric proteins are capable of, or finduse in methods comprising, stimulating or enhancing the binding of theimmune stimulatory receptor/ligand pair: CD40:CD40L. In embodiments, thepresent chimeric protein increases and/or stimulates CD40 and/or thebinding of CD40 with one or more of CD40L.

In embodiments, a chimeric protein comprises an extracellular domain oftype II protein, other than CD40L. Exemplary type II proteins include4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L, TL1A, and TRAIL. The presentinvention further includes chimeric proteins and methods using thefollowing chimeric proteins: CSF1R/4-1BBL, CSF1R/CD30L, CSF1R/FasL,CSF1R/GITRL, CSF1R/LIGHT, CSF1R/OX40L, CSF1R/TL1A, and CSF1R/TRAIL. Inembodiments, the chimeric protein has a general structure of one ofCSF1R-Fc-4-1BBL, CSF1R-Fc-CD30L, CSF1R-Fc-FasL, CSF1R-Fc-GITRL,CSF1R-Fc-LIGHT, CSF1R-Fc-OX40L, CSF1R-Fc-TL1A, and CSF1R-Fc-TRAIL.

The amino acid sequence for 4-1BBL, CD3OL, FasL, GITRL, LIGHT, OX40L,TL1A, and TRAIL, respectively, comprises SEQ ID NO: 9, 11, 13, 15, 17,6, 21, and 23.

In embodiments, a chimeric protein comprises the extracellular domain ofone of 4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L, TL1A, and TRAIL which,respectively, comprises SEQ ID NO: 10, 12, 14, 16, 18, 7, 22, and 24. Inembodiments, the present chimeric proteins may comprise theextracellular domain of 4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L, TL1A,or TRAIL as described herein, or a variant or a functional fragmentthereof. For instance, the chimeric protein may comprise a sequence ofthe extracellular domain of 4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L,TL1A, or TRAIL as provided above, or a variant or functional fragmentthereof having at least about 60%, or at least about 61%, or at leastabout 62%, or at least about 63%, or at least about 64%, or at leastabout 65%, or at least about 66%, or at least about 67%, or at leastabout 68%, or at least about 69%, or at least about 70%, or at leastabout 71%, or at least about 72%, or at least about 73%, or at leastabout 74%, or at least about 75%, or at least about 76%, or at leastabout 77%, or at least about 78%, or at least about 79%, or at leastabout 80%, or at least about 81%, or at least about 82%, or at leastabout 83%, or at least about 84%, or at least about 85%, or at leastabout 86%, or at least about 87%, or at least about 88%, or at leastabout 89%, or at least about 90%, or at least about 91%, or at leastabout 92%, or at least about 93%, or at least about 94%, or at leastabout 95%, or at least about 96%, or at least about 97%, or at leastabout 98%, or at least about 99% sequence identity with the amino acidsequence of the extracellular domain of 4-1BBL, CD30L, FasL, GITRL,LIGHT, OX40L, TL1A, or TRAIL as described herein.

In embodiments, the chimeric protein of the invention delivers an immunestimulation to an immune cell (e.g., an antigen presenting cell) whileproviding a localized trap or sequester of immune inhibitory signals. Inembodiments, the chimeric protein delivers signals that have the netresult of immune activation.

In embodiments, the present chimeric proteins are capable of, and can beused in methods comprising, promoting immune activation (e.g., againsttumors). In embodiments, the present chimeric proteins are capable of,and can be used in methods comprising, suppressing immune inhibition(e.g., that allows tumors to survive). In embodiments, the presentchimeric proteins provide improved immune activation and/or improvedsuppression of immune inhibition due to the proximity of signaling thatis provided by the chimeric nature of the constructs.

In embodiments, the present chimeric proteins are capable of, or can beused in methods comprising, modulating the amplitude of an immuneresponse, e.g., modulating the level of effector output. In embodiments,e.g., when used for the treatment of a cancer and/or an inflammatorydisease, the present chimeric proteins alter the extent of immunestimulation as compared to immune inhibition to increase the amplitudeof a T cell response, including, without limitation, stimulatingincreased levels of cytokine production, proliferation or target killingpotential.

In embodiments, the present chimeric proteins are capable of, or finduse in methods involving, masking an inhibitory ligand on the surface ofa tumor cell and replacing that immune inhibitory ligand with an immunestimulatory ligand. For example, the present chimeric protein comprises(a) an extracellular domain of CSF1R and (b) an extracellular domain ofCD40L, allows for the disruption of an inhibitory CSF1/CSF1R signal andreplacing it with a stimulating CD40L/CD40 signal. Accordingly, thepresent chimeric proteins, in embodiments are capable of, or find use inmethods involving, reducing or eliminating an inhibitory immune signaland/or increasing or activating an immune stimulatory signal. Forexample, a tumor comprising an inhibitory signal (and thus evading animmune response) may be substituted for a positive signal binding on amacrophage or a T cell that can then attack a tumor cell. Accordingly,in embodiments, an inhibitory immune signal is masked by the presentconstructs and a stimulatory immune signal is activated. Such beneficialproperties are enhanced by the single construct approach of the presentchimeric proteins. For instance, the signal replacement can be effectednearly simultaneously, e.g., contemporaneously, and the signalreplacement is tailored to be local at a site of clinical importance(e.g., the tumor microenvironment).

In embodiments, the present chimeric proteins are capable of, or finduse in methods involving, enhancing, restoring, promoting and/orstimulating immune modulation. In embodiments, the present chimericproteins described herein, restore, promote and/or stimulate theactivity or activation of one or more immune cells against tumor cellsincluding, but not limited to: T cells, cytotoxic T lymphocytes, Thelper cells, natural killer (NK) cells, natural killer T (NKT) cells,anti-tumor macrophages (e.g., M1 macrophages), B cells, and dendriticcells. In embodiments, the present chimeric proteins enhance, restore,promote and/or stimulate the activity and/or activation of T cells,including, by way of a non-limiting example, activating and/orstimulating one or more T-cell intrinsic signals, including apro-survival signal; an autocrine or paracrine growth signal; a p38MAPK-, ERK-, STAT-, JAK-, AKT- or PI3K-mediated signal; ananti-apoptotic signal; and/or a signal promoting and/or necessary forone or more of: proinflammatory cytokine production or T cell migrationor T cell tumor infiltration.

In embodiments, the present chimeric proteins are capable of, or finduse in methods involving, causing an increase of one or more of T cells(including without limitation cytotoxic T lymphocytes, T helper cells,natural killer T (NKT) cells), B cells, natural killer (NK) cells,natural killer T (NKT) cells, dendritic cells, monocytes, andmacrophages (e.g., one or more of M1 and M2) into a tumor or the tumormicroenvironment. In embodiments, the chimeric protein enhancesrecognition of tumor antigens by CD8+ T cells, particularly those Tcells that have infiltrated into the tumor microenvironment. Inembodiments, the present chimeric protein induces CD19 expression and/orincreases the number of CD19 positive cells (e.g., CD19 positive Bcells). In an embodiment, the present chimeric protein induces IL-15Rαexpression and/or increases the number of IL-15Rα positive cells (e.g.,IL-15Rα positive dendritic cells).

In embodiments, the present chimeric proteins are capable of, or finduse in methods involving, inhibiting and/or causing a decrease inimmunosuppressive cells (e.g., myeloid-derived suppressor cells (MDSCs),regulatory T cells (Tregs), tumor associated neutrophils (TANs), M2macrophages, and tumor associated macrophages (TAMs)), and particularlywithin the tumor and/or tumor microenvironment (TME). In embodiments,the present therapies may alter the ratio of M1 versus M2 macrophages inthe tumor site and/or TME to favor M1 macrophages.

In embodiments, the present chimeric proteins are capable of, and can beused in methods comprising, inhibiting and/or reducing T cellinactivation and/or immune tolerance to a tumor, comprisingadministering an effective amount of a chimeric protein described hereinto a subject. In embodiments, the present chimeric proteins are able toincrease the serum levels of various cytokines including, but notlimited to, one or more of IFNγ, TNFα, IL-2, IL-4, IL-5, IL-6, IL-9,IL-10, IL-13, IL-17A, IL-17F, and IL-22. In embodiments, the presentchimeric proteins are capable of enhancing IL-2, IL-4, IL-5, IL-10,IL-13, IL-17A, IL-22, TNFα, or IFNγ in the serum of a treated subject.Detection of such a cytokine response may provide a method to determinethe optimal dosing regimen for the indicated chimeric protein.

In embodiments, the present chimeric proteins inhibit, block and/orreduce cell death of an anti-tumor CD8+ and/or CD4+ T cell; orstimulate, induce, and/or increase cell death of a pro-tumor T cell. Tcell exhaustion is a state of T cell dysfunction characterized byprogressive loss of proliferative and effector functions, culminating inclonal deletion. Accordingly, a pro-tumor T cell refers to a state of Tcell dysfunction that arises during many chronic infections,inflammatory diseases, and cancer. This dysfunction is defined by poorproliferative and/or effector functions, sustained expression ofinhibitory receptors and a transcriptional state distinct from that offunctional effector or memory T cells. Exhaustion prevents optimalcontrol of infection and tumors. Illustrative pro-tumor T cells include,but are not limited to, Tregs, CD4+ and/or CD8+ T cells expressing oneor more checkpoint inhibitory receptors, Th2 cells and Th17 cells.Checkpoint inhibitory receptors refer to receptors expressed on immunecells that prevent or inhibit uncontrolled immune responses. Incontrast, an anti-tumor CD8+ and/or CD4+ T cell refers to T cells thatcan mount an immune response to a tumor.

In embodiments, the present chimeric proteins are capable of, and can beused in methods comprising, increasing a ratio of effector T cells toregulatory T cells. Illustrative effector T cells include ICOS⁺ effectorT cells; cytotoxic T cells (e.g., αβ0 TCR, CD3⁺, CD8⁺, CD45RO⁺); CD4⁺effector T cells (e.g., αβ TCR, CD3⁺, CD4⁺, CCR7⁺, CD62Lhi,IL-7R/CD127⁺); CD8⁺ effector T cells (e.g., αβ TCR, CD3⁺, CD8⁺, CCR7⁺,CD62Lhi, IL-7R/CD127⁺; effector memory T cells (e.g., CD62Llow, CD44⁺,TCR, CD3⁺, IL-7R/CD127⁺, IL-15R⁺, CCR7low); central memory T cells(e.g., CCR7⁺, CD62L⁺, CD27⁺; or CCR7hi, CD44⁺, CD62Lhi, TCR, CD3⁺,IL-7R/CD127⁺, IL-15R⁺); CD62L⁺ effector T cells; CD8⁺ effector memory Tcells (TEM) including early effector memory T cells (CD27⁺ CD62L⁻) andlate effector memory T cells (CD27⁻CD62L⁻) (TemE and TemL,respectively); CD127(⁺)CD25(low/-) effector T cells; CD127(⁻)CD25(⁻)effector T cells; CD8⁺ stem cell memory effector cells (TSCM) (e.g.,CD44(low)CD62L(high)CD122(high)sca(⁺); TH1 effector T-cells (e.g.,CXCR3⁺, CXCR6⁺ and CCR5⁺; or αβ TCR, CD3⁺, CD4⁺, IL-12R⁺, IFNγR⁺,CXCR3⁺), TH2 effector T cells (e.g., CCR3⁺, CCR4⁺ and CCR8⁺; or αβ TCR,CD3⁺, CD4⁺, IL-4R⁺, IL-33R⁺, CCR4⁺, IL-17RB⁺, CRTH2⁺); TH9 effector Tcells (e.g., αβ TCR, CD3⁺, CD4⁺); TH17 effector T cells (e.g., αβ TCR,CD3⁺, CD4⁺, IL-23R⁺, CCR6⁺, IL-1R⁺); CD4⁺CD45RO⁺CCR7⁺ effector T cells,CD4⁺CD45RO⁺CCR7(⁻) effector T cells; and effector T cells secretingIL-2, IL-4 and/or IFN-γ. Illustrative regulatory T cells include ICOS⁺regulatory T cells, CD4⁺CD25⁺FOXP3⁺ regulatory T cells, CD4⁺CD25⁺regulatory T cells, CD4⁺CD25⁻ regulatory T cells, CD4⁺CD25highregulatory T cells, TIM-3⁺PD-1⁺ regulatory T cells, lymphocyteactivation gene-3 (LAG-3)⁺ regulatory T cells, CTLA-4/CD152⁺ regulatoryT cells, neuropilin-1 (Nrp-1)⁺ regulatory T cells, CCR4+CCR8⁺ regulatoryT cells, CD62L (L-selectin)⁺ regulatory T cells, CD45RBlow regulatory Tcells, CD127low regulatory T cells, LRRC32/GARP⁺ regulatory T cells,CD39⁺ regulatory T cells, GITR⁺ regulatory T cells, LAP⁺ regulatory Tcells, 1B11⁺ regulatory T cells, BTLA⁺ regulatory T cells, type 1regulatory T cells (Tr1 cells), T helper type 3 (Th3) cells, regulatorycell of natural killer T cell phenotype (NKTregs), CD8⁺ regulatory Tcells, CD8⁺CD28⁻ regulatory T cells and/or regulatory T-cells secretingIL-10, IL-35, TGF-β, TNF-α, Galectin-1, IFN-γ and/or MCP1.

In embodiments, the chimeric protein of the invention causes an increasein effector T cells (e.g., CD4+CD25− T cells).

In embodiments, the chimeric protein causes a decrease in regulatory Tcells (e.g., CD4+CD25+ T cells).

In embodiments, the chimeric protein generates a memory response whichmay, e.g., be capable of preventing relapse or protecting the animalfrom a rechallenge. Thus, an animal treated with the chimeric protein islater able to attack tumor cells and/or prevent development of tumorswhen rechallenged after an initial treatment with the chimeric protein.Accordingly, a chimeric protein of the present invention stimulates bothactive tumor destruction and also immune recognition of tumor antigens,which are essential in programming a memory response capable ofpreventing relapse.

In embodiments, the present chimeric proteins are capable of, and can beused in methods comprising, transiently stimulating effector immunecells for no longer than about 12 hours, about 24 hours, about 48 hours,about 72 hours or about 96 hours or about 1 week or about 2 weeks. Inembodiments, the present chimeric proteins are capable of, and can beused in methods comprising, transiently depleting or inhibitingregulatory or immune suppressive cells for no longer than about 12hours, about 24 hours, about 48 hours, about 72 hours or about 96 hoursor about 1 week or about 2 weeks. In embodiments, the transientstimulation of effector T cells and/or transient depletion or inhibitionof immune inhibitory cells occurs substantially in a patient'sbloodstream or in a particular tissue/location including lymphoidtissues such as for example, the bone marrow, lymph-node, spleen,thymus, mucosa-associated lymphoid tissue (MALT), non-lymphoid tissues,or in the tumor microenvironment.

In embodiments, the present chimeric proteins provide advantagesincluding, without limitation, ease of use and ease of production. Thisis because two distinct immunotherapy agents are combined into a singleproduct which allows for a single manufacturing process instead of twoindependent manufacturing processes. In addition, administration of asingle agent instead of two separate agents allows for easieradministration and greater patient compliance.

In embodiments, the present chimeric protein is producible in amammalian host cell as a secretable and fully functional singlepolypeptide chain.

In embodiments, the present chimeric protein unexpectedly providesbinding of the extracellular domain components to their respectivebinding partners with slow off rates (Kd or K_(off)). In embodiments,this provides an unexpectedly long interaction of the receptor to ligandand vice versa. Such an effect allows for a sustained negative signalmasking effect. Further, in embodiments, this delivers a longer positivesignal effect, e.g., to allow an effector cell to be adequatelystimulated for an anti-tumor effect. For example, the present chimericprotein, e.g., via the long off rate binding allows sufficient signaltransmission to provide immune cell proliferation and allow foranti-tumor attack. By way of further example, the present chimericprotein, e.g., via the long off rate binding allows sufficient signaltransmission to provide release of stimulatory signals, such as, forexample, cytokines.

The stable synapse of cells promoted by the present agents (e.g. a tumorcell bearing negative signals and a T cell which could attack the tumor)provides spatial orientation to favor tumor reduction—such aspositioning the T cells to attack tumor cells and/or stericallypreventing the tumor cell from delivering negative signals, includingnegative signals beyond those masked by the chimeric protein of theinvention.

In embodiments, the present chimeric protein exhibits a Kd (1/s) forhuman CSF1 or IL-34 of more than about 2×10⁶, about 2.5×10⁶, about3×10⁶, about 3.5×10⁶, about 4×10⁶, about 4.5×10⁶, about 5×10⁶, about5.5×10⁶, about 6×10⁶, about 6.5×10⁶, about 7×10⁶, about 7.5×10⁶, about8×10⁶, about 8.5×10⁶, about 9×10⁶, or about 9.5×10⁶ (as measured, forexample, by surface plasmon resonance or biolayer interferometry). Inembodiments, the chimeric protein binds to human CSF1 with a K_(D) offrom about 100 pM to about 600 pM. In embodiments, the chimeric proteinbinds to human CSF1 with a K_(a) on rate (1/Ms) of about 5.7×10⁴ andunbinds from human CSF1 with a K_(d) on rate (1/s) of about 7.3×10⁻⁶.

In embodiments, the present chimeric protein exhibits a Kd (1/s) forhuman CD40 of more than about 2×10⁶, about 2.5×10⁶, about 3×10⁶, about3.5×10⁶, about 4×10⁶, about 4.5×10⁶, about 5×10⁶, about 5.5×10⁶, about6×10⁶, about 6.5×10⁶, about 7×10⁶, about 7.5×10⁶, about 8×10⁶, about8.5x10⁶, about 9×10⁶, or about 9.5×10⁶ (as measured, for example, bysurface plasmon resonance or biolayer interferometry). In embodiments,the chimeric protein binds to human CD40 with a K_(a) on rate (1/Ms) ofabout 1.3×10⁴ and unbinds from human CD40 with a K_(d) off rate (1/s) ofabout 6.7×10⁻⁶.

In embodiments, this provides longer on-target (e.g., intra-tumoral)half-life (t_(1/2)) as compared to serum t1/2 of the chimeric proteins.Such properties could have the combined advantage of reducing off-targettoxicities associated with systemic distribution of the chimericproteins.

Indeed, has been reported that sequential treatments with CSF1 blockingantibodies and CD40 agonist antibodies, for example, induce livertoxicity. See, e.g., Byrne et al. J. Immunology, 2016. Data disclosedherein (See, e.g., FIG. 13) similarly show that the two antibodies arehighly toxic when co-administered to mice and cause lethal gutinflammation and diarrhea. In contrast and surprisingly, treatments witha CSF1R-Fc-CD40L chimeric protein blocks CSF1R (which inhibits thetransmission of an immune inhibitory signal) and activates CD40 (whichenhances, increases, and/or stimulates the transmission of an immunestimulatory signal), yet without the toxicity resulting from antibodyco-treatments. Further, in embodiments, the present chimeric proteinsprovide synergistic therapeutic effects (e.g., anti-tumor effects) as itallows for improved site-specific interplay of two immunotherapy agents.In embodiments, the present chimeric proteins provide synergistictherapeutic effects when compared to CD40 agonist antibodies and/orCSF1R antagonistic antibodies. In embodiments, the present chimericproteins provide the potential for reducing off-site and/or systemictoxicity.

In embodiments, the present chimeric protein exhibit enhanced safetyprofiles. In embodiment, the present chimeric protein exhibit reducedtoxicity profiles. For example, administration of the present chimericprotein may result in reduced side effects such as one or more ofdiarrhea, inflammation (e.g., of the gut), or weight loss, which areobserved with administration of CD40 agonist antibodies and/or CD115antagonistic antibodies. In embodiments, the present chimeric proteinprovides improved safety, as compared to CD40 agonist antibodies and/orCD115 antagonistic antibodies, without sacrificing efficacy.

In embodiments, the present chimeric proteins provide reducedside-effects, e.g., GI complications, relative to currentimmunotherapies, e.g., antibodies directed to checkpoint moleclues asdescribed herein. Illustrative GI complications include abdominal pain,appetite loss, autoimmune effects, constipation, cramping, dehydration,diarrhea, eating problems, fatigue, flatulence, fluid in the abdomen orascites, gastrointestinal (GI) dysbiosis, GI mucositis, inflammatorybowel disease, irritable bowel syndrome (IBS-D and IBS-C), nausea, pain,stool or urine changes, ulcerative colitis, vomiting, weight gain fromretaining fluid, and/or weakness.

Diseases, Methods of Treatment, and Patient Selections

In embodiments, the present invention pertains to cancers and/or tumors;for example, the treatment or prevention of cancers and/or tumors. Asdescribed elsewhere herein, the treatment of cancer may involve inembodiments, modulating the immune system with the present chimericproteins to favor immune stimulation over immune inhibition.

Cancers or tumors refer to an uncontrolled growth of cells and/orabnormal increased cell survival and/or inhibition of apoptosis whichinterferes with the normal functioning of the bodily organs and systems.Included are benign and malignant cancers, polyps, hyperplasia, as wellas dormant tumors or micrometastases. Also, included are cells havingabnormal proliferation that is not impeded by the immune system (e.g.,virus infected cells). The cancer may be a primary cancer or ametastatic cancer. The primary cancer may be an area of cancer cells atan originating site that becomes clinically detectable, and may be aprimary tumor. In contrast, the metastatic cancer may be the spread of adisease from one organ or part to another non-adjacent organ or part.The metastatic cancer may be caused by a cancer cell that acquires theability to penetrate and infiltrate surrounding normal tissues in alocal area, forming a new tumor, which may be a local metastasis. Thecancer may also be caused by a cancer cell that acquires the ability topenetrate the walls of lymphatic and/or blood vessels, after which thecancer cell is able to circulate through the bloodstream (thereby beinga circulating tumor cell) to other sites and tissues in the body. Thecancer may be due to a process such as lymphatic or hematogeneousspread. The cancer may also be caused by a tumor cell that comes to restat another site, re-penetrates through the vessel or walls, continues tomultiply, and eventually forms another clinically detectable tumor. Thecancer may be this new tumor, which may be a metastatic (or secondary)tumor.

The cancer may be caused by tumor cells that have metastasized, whichmay be a secondary or metastatic tumor. The cells of the tumor may belike those in the original tumor. As an example, if a breast cancer orcolon cancer metastasizes to the liver, the secondary tumor, whilepresent in the liver, is made up of abnormal breast or colon cells, notof abnormal liver cells. The tumor in the liver may thus be a metastaticbreast cancer or a metastatic colon cancer, not liver cancer.

The cancer may have an origin from any tissue. The cancer may originatefrom melanoma, colon, breast, or prostate, and thus may be made up ofcells that were originally skin, colon, breast, or prostate,respectively. The cancer may also be a hematological malignancy, whichmay be leukemia or lymphoma. The cancer may invade a tissue such asliver, lung, bladder, or intestinal.

Representative cancers and/or tumors of the present invention include,but are not limited to, a basal cell carcinoma, biliary tract cancer;bladder cancer; bone cancer; brain and central nervous system cancer;breast cancer; cancer of the peritoneum; cervical cancer;choriocarcinoma; colon and rectum cancer; connective tissue cancer;cancer of the digestive system; endometrial cancer; esophageal cancer;eye cancer; cancer of the head and neck; gastric cancer (includinggastrointestinal cancer); glioblastoma; hepatic carcinoma; hepatoma;intra-epithelial neoplasm; kidney or renal cancer; larynx cancer;leukemia; liver cancer; lung cancer (e.g., small-cell lung cancer,non-small cell lung cancer, adenocarcinoma of the lung, and squamouscarcinoma of the lung); melanoma; myeloma; neuroblastoma; oral cavitycancer (lip, tongue, mouth, and pharynx); ovarian cancer; pancreaticcancer; prostate cancer; retinoblastoma; rhabdomyosarcoma; rectalcancer; cancer of the respiratory system; salivary gland carcinoma;sarcoma; skin cancer; squamous cell cancer; stomach cancer; testicularcancer; thyroid cancer; uterine or endometrial cancer; cancer of theurinary system; vulval cancer; lymphoma including Hodgkin's andnon-Hodgkin's lymphoma, as well as B-cell lymphoma (including lowgrade/follicular non-Hodgkin's lymphoma (NHL); small lymphocytic (SL)NHL; intermediate grade/follicular NHL; intermediate grade diffuse NHL;high grade immunoblastic NHL; high grade lymphoblastic NHL; high gradesmall non-cleaved cell NHL; bulky disease NHL; mantle cell lymphoma;AIDS-related lymphoma; and Waldenstrom's Macroglobulinemia; chroniclymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); Hairycell leukemia; chronic myeloblastic leukemia; as well as othercarcinomas and sarcomas; and post-transplant lymphoproliferativedisorder (PTLD), as well as abnormal vascular proliferation associatedwith phakomatoses, edema (such as that associated with brain tumors),and Meigs' syndrome.

In embodiments, the chimeric protein is used to treat a subject that hasa treatment-refractory cancer. In embodiments, the chimeric protein isused to treat a subject that is refractory to one or moreimmune-modulating agents. For example, in embodiments, the chimericprotein is used to treat a subject that presents no response totreatment, or even progress, after 12 weeks or so of treatment. Forinstance, in embodiments, the subject is refractory to a PD-1 and/orPD-L1 and/or PD-L2 agent, including, for example, nivolumab(ONO-4538/BMS-936558, MDX1106, OPDIVO, BRISTOL MYERS SQUIBB),pembrolizumab (KEYTRUDA, MERCK), pidilizumab (CT-011, CURE TECH),MK-3475 (MERCK), BMS 936559 (BRISTOL MYERS SQUIBB), Ibrutinib(PHARMACYCLICS/ABBVIE), atezolizumab (TECENTRIQ, GENENTECH), and/orMPDL328OA (ROCHE)-refractory patients. For instance, in embodiments, thesubject is refractory to an anti-CTLA-4 agent, e.g., ipilimumab(YERVOY)-refractory patients (e.g., melanoma patients). Accordingly, inembodiments the present invention provides methods of cancer treatmentthat rescue patients that are non-responsive to various therapies,including monotherapy of one or more immune-modulating agents.

In embodiments, the present methods provide treatment with the chimericprotein in a patient who is refractory to an additional agent, such“additional agents” being described elsewhere herein, inclusive, withoutlimitation, of the various chemotherapeutic agents described herein.

In embodiments, the chimeric proteins are used to treat, control orprevent one or more inflammatory diseases or conditions. Non-limitingexamples of inflammatory diseases include acne vulgaris, acuteinflammation, allergic rhinitis, asthma, atherosclerosis, atopicdermatitis, autoimmune disease, autoinflammatory diseases, autosomalrecessive spastic ataxia, bronchiectasis, celiac disease, chroniccholecystitis, chronic inflammation, chronic prostatitis, colitis,diverticulitis, familial eosinophilia (fe), glomerulonephritis, glycerolkinase deficiency, hidradenitis suppurativa, hypersensitivities,inflammation, inflammatory bowel diseases, inflammatory pelvic disease,interstitial cystitis, laryngeal inflammatory disease, Leigh syndrome,lichen planus, mast cell activation syndrome, mastocytosis, ocularinflammatory disease, otitis, pain, pelvic inflammatory disease,reperfusion injury, respiratory disease, restenosis, rheumatic fever,rheumatoid arthritis, rhinitis, sarcoidosis, septic shock, silicosis andother pneumoconioses, transplant rejection, tuberculosis, andvasculitis.

In embodiments, the inflammatory disease is an autoimmune disease orcondition, such as multiple sclerosis, diabetes mellitus, lupus, celiacdisease, Crohn's disease, ulcerative colitis, Guillain-Barre syndrome,scleroderms, Goodpasture's syndrome, Wegener's granulomatosis,autoimmune epilepsy, Rasmussen's encephalitis, Primary biliarysclerosis, Sclerosing cholangitis, Autoimmune hepatitis, Addison'sdisease, Hashimoto's thyroiditis, Fibromyalgia, Menier's syndrome;transplantation rejection (e.g., prevention of allograft rejection)pernicious anemia, rheumatoid arthritis, systemic lupus erythematosus,dermatomyositis, Sjogren's syndrome, lupus erythematosus, multiplesclerosis, myasthenia gravis, Reiter's syndrome, Grave's disease, andother autoimmune diseases.

In aspects, the present chimeric agents are used in methods ofactivating an antigen presenting cell, e.g., via the extracellulardomain of CD40L. In aspects, the present chimeric agents are used inmethods of preventing the cellular transmission of an immunosuppressivesignal via the extracellular domain of CSF1R.

Combination Therapies and Conjugation

In embodiments, the invention provides for chimeric proteins and methodsthat further comprise administering an additional agent to a subject. Inembodiments, the invention pertains to co-administration and/orco-formulation. Any of the compositions described herein may beco-formulated and/or co-administered.

In embodiments, any chimeric protein described herein actssynergistically when co-administered with another agent and isadministered at doses that are lower than the doses commonly employedwhen such agents are used as monotherapy. In embodiments, any agentreferenced herein may be used in combination with any of the chimericproteins described herein.

In embodiments, the present chimeric protein comprising theextracellular domain of CSF1R as described herein is co-administeredwith another chimeric protein. In embodiments, the present chimericprotein comprising the extracellular domain of CSF1R as described hereinis co-administered with another chimeric protein, for example, one whichmodulates the adaptive immune response. In embodiments, the presentchimeric protein comprising the extracellular domain of CSF1R asdescribed herein is co-administered with a chimeric protein comprisingone or more of OX40L, PD-1, GITRL, 4-1BBL, SIRPα, TIM3, TIGIT, LIGHT andVSIG8. Without wishing to be bound by theory, it is believed that acombined regimen involving the administration of the present chimericprotein which induces an innate immune response and one or more chimericproteins which induces an adaptive immune response may providesynergistic effects (e.g., synergistic anti-tumor effects).

Any chimeric protein which induces an adaptive immune response may beutilized in the present invention. For example, the chimeric protein maybe any of the chimeric proteins disclosed in U.S. Pat. No. 62/464,002which induce an adaptive immune response. In such embodiments, thechimeric protein comprises a first extracellular domain of a type Itransmembrane protein at or near the N-terminus and a secondextracellular domain of a type II transmembrane protein at or near theC-terminus, wherein one of the first and second extracellular domainsprovides an immune inhibitory signal and one of the first and secondextracellular domains provides an immune stimulatory signal as disclosedin U.S. Pat. No. 62/464,002, the entire contents of which is herebyincorporated by reference. In an exemplary embodiment, the chimericprotein which induces an adaptive immune response is a chimeric proteincomprising the extracellular domain of PD-1 at the N-terminus and theextracellular domain of OX40L, GITRL, or 4-1BBL at the C-terminus. In anembodiment, the chimeric protein which induces an adaptive immuneresponse is a chimeric protein comprising the extracellular domain ofVSIG8 at the N-terminus and the extracellular domain of OX40L, GITRL, or4-1BBL at the C-terminus.

In embodiments, the present chimeric protein comprising theextracellular domain of CSF1R as described herein is administered to apatient to stimulate the innate immune response and, subsequently (e.g.,1 day later, or 2 days later, or 3 days later, or 4 days later, or 5days later, or 6 days later, or 1 week later, or 2 weeks later, or 3weeks later, or 4 weeks later) a chimeric protein which induce anadaptive immune response is administered.

In embodiments, inclusive of, without limitation, cancer applications,the present invention pertains to chemotherapeutic agents as additionalagents. Examples of chemotherapeutic agents include, but are not limitedto, alkylating agents such as thiotepa and CYTOXAN cyclosphosphamide;alkyl sulfonates such as busulfan, improsulfan and piposulfan;aziridines such as benzodopa, carboquone, meturedopa, and uredopa;ethylenimines and methylamelamines including altretamine,triethylenemelamine, trietylenephosphoramide,triethiylenethiophosphoramide and trimethylolomelamine; acetogenins(e.g., bullatacin and bullatacinone); a camptothecin (including thesynthetic analogue topotecan); bryostatin; cally statin; CC-1065(including its adozelesin, carzelesin and bizelesin syntheticanalogues); cryptophycins (e.g., cryptophycin 1 and cryptophycin 8);dolastatin; duocarmycin (including the synthetic analogues, KW-2189 andCB 1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin;nitrogen mustards such as chlorambucil, chlornaphazine,cholophosphamide, estramustine, ifosfamide, mechlorethamine,mechlorethamine oxide hydrochloride, melphalan, novembichin,phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureassuch as carmustine, chlorozotocin, fotemustine, lomustine, nimustine,and ranimnustine; antibiotics such as the enediyne antibiotics (e.g.,calicheamicin, especially calicheamicin gammall and calicheamicinomegall (see, e.g., Agnew, Chem. Intl. Ed. Engl., 33: 183-186 (1994));dynemicin, including dynemicin A; bisphosphonates, such as clodronate;an esperamicin; as well as neocarzinostatin chromophore and relatedchromoprotein enediyne antibiotic chromophores), aclacinomysins,actinomycin, authramycin, azaserine, bleomycins, cactinomycin,carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin,daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, ADRIAMYCINdoxorubicin (including morpholino-doxorubicin,cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin,mitomycins such as mitomycin C, mycophenolic acid, nogalamycin,olivomycins, peplomycin, potfiromycin, puromycin, quelamycin,rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex,zinostatin, zorubicin; anti-metabolites such as methotrexate and5-fluorouracil (5-FU); folic acid analogues such as denopterin,methotrexate, pteropterin, trimetrexate; purine analogs such asfludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidineanalogs such as ancitabine, azacitidine, 6-azauridine, carmofur,cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine;androgens such as calusterone, dromostanolone propionate, epitiostanol,mepitiostane, testolactone; anti-adrenals such as minoglutethimide,mitotane, trilostane; folic acid replenisher such as frolinic acid;aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil;amsacrine; bestrabucil; bisantrene; edatraxate; demecolcine; diaziquone;elformithine; elliptinium acetate; an epothilone; etoglucid; galliumnitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such asmaytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol;nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone;podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK polysaccharidecomplex (JHS Natural Products, Eugene, Oreg.); razoxane; rhizoxin;sizofuran; spirogermanium; tenuazonic acid; triaziquone;2,2′,2″-trichlorotriethylamine; trichothecenes (e.g., T-2 toxin,verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine;mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine;arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g., TAXOLpaclitaxel (Bristol-Myers Squibb Oncology, Princeton, N.J.), ABRAXANECremophor-free, albumin-engineered nanoparticle formulation ofpaclitaxel (American Pharmaceutical Partners, Schaumberg, 111.), andTAXOTERE doxetaxel (Rhone-Poulenc Rorer, Antony, France); chloranbucil;GEMZAR gemcitabine; 6-thioguanine; mercaptopurine; methotrexate;platinum analogs such as cisplatin, oxaliplatin and carboplatin;vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone;vincristine; NAVELBINE. vinorelbine; novantrone; teniposide; edatrexate;daunomycin; aminopterin; xeloda; ibandronate; irinotecan (Camptosar,CPT-11) (including the treatment regimen of irinotecan with 5-FU andleucovorin); topoisomerase inhibitor RFS 2000; difluoromethylornithine(DMFO); retinoids such as retinoic acid; capecitabine; combretastatin;leucovorin (LV); oxaliplatin, including the oxaliplatin treatmentregimen (FOLFOX); lapatinib (TYKERB); inhibitors of PKC-α, Raf, H-Ras,EGFR (e.g., erlotinib (Tarceva)) and VEGF-A that reduce cellproliferation and pharmaceutically acceptable salts, acids orderivatives of any of the above. In addition, the methods of treatmentcan further include the use of radiation. In addition, the methods oftreatment can further include the use of photodynamic therapy.

In embodiments, inclusive of, without limitation, cancer applications,the present additional agent is one or more immune-modulating agentsselected from an agent that blocks, reduces and/or inhibits PD-1 andPD-L1 or PD-L2 and/or the binding of PD-1 with PD-L1 or PD-L2 (by way ofnon-limiting example, one or more of nivolumab (ONO-4538/BMS-936558,MDX1106, OPDIVO, BRISTOL MYERS SQUIBB), pembrolizumab (KEYTRUDA, Merck),pidilizumab (CT-011, CURE TECH), MK-3475 (MERCK), BMS 936559 (BRISTOLMYERS SQUIBB), atezolizumab (TECENTRIQ, GENENTECH), MPDL328OA (ROCHE)),an agent that increases and/or stimulates CD137 (4-1BB) and/or thebinding of CD137 (4-1BB) with one or more of 4-1BB ligand (by way ofnon-limiting example, urelumab (BMS-663513 and anti-4-1BB antibody), andan agent that blocks, reduces and/or inhibits the activity of CTLA-4and/or the binding of CTLA-4 with one or more of AP2M1, CD80, CD86,SHP-2, and PPP2R5A and/or the binding of OX40 with OX40L (by way ofnon-limiting example GBR 830 (GLENMARK), MED16469 (MEDIMMUNE).

In embodiments, inclusive of, without limitation, infectious diseaseapplications, the present invention pertains to anti-infectives asadditional agents. In embodiments, the anti-infective is an anti-viralagent including, but not limited to, Abacavir, Acyclovir, Adefovir,Amprenavir, Atazanavir, Cidofovir, Darunavir, Delavirdine, Didanosine,Docosanol, Efavirenz, Elvitegravir, Emtricitabine, Enfuvirtide,Etravirine, Famciclovir, and Foscarnet. In embodiments, theanti-infective is an anti-bacterial agent including, but not limited to,cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil,cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, andceftobiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin,tequin, avelox, and norflox); tetracycline antibiotics (tetracycline,minocycline, oxytetracycline, and doxycycline); penicillin antibiotics(amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin,vancomycin, and methicillin); monobactam antibiotics (aztreonam); andcarbapenem antibiotics (ertapenem, doripenem, imipenem/cilastatin, andmeropenem). In embodiments, the anti-infectives include anti-malarialagents (e.g., chloroquine, quinine, mefloquine, primaquine, doxycycline,artemether/lumefantrine, atovaquone/proguanil andsulfadoxine/pyrimethamine), metronidazole, tinidazole, ivermectin,pyrantel pamoate, and albendazole.

In embodiments, inclusive, without limitation, of autoimmuneapplications, the additional agent is an immunosuppressive agent. Inembodiments, the immunosuppressive agent is an anti-inflammatory agentsuch as a steroidal anti-inflammatory agent or a non-steroidalanti-inflammatory agent (NSAID). Steroids, particularly the adrenalcorticosteroids and their synthetic analogues, are well known in theart. Examples of corticosteroids useful in the present inventioninclude, without limitation, hydroxyltriamcinolone, alpha-methyldexamethasone, beta-methyl betamethasone, beclomethasone dipropionate,betamethasone benzoate, betamethasone dipropionate, betamethasonevalerate, clobetasol valerate, desonide, desoxymethasone, dexamethasone,diflorasone diacetate, diflucortolone valerate, fluadrenolone,fluclorolone acetonide, flumethasone pivalate, fluosinolone acetonide,fluocinonide, flucortine butylester, fluocortolone, fluprednidene(fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisoneacetate, hydrocortisone butyrate, methylprednisolone, triamcinoloneacetonide, cortisone, cortodoxone, flucetonide, fludrocortisone,difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel,amcinafide, betamethasone and the balance of its esters,chloroprednisone, clocortelone, clescinolone, dichlorisone,difluprednate, flucloronide, flunisolide, fluoromethalone, fluperolone,fluprednisolone, hydrocortisone, meprednisone, paramethasone,prednisolone, prednisone, beclomethasone dipropionate. (NSAIDS) that maybe used in the present invention, include but are not limited to,salicylic acid, acetyl salicylic acid, methyl salicylate, glycolsalicylate, salicylmides, benzyl-2,5-diacetoxybenzoic acid, ibuprofen,fulindac, naproxen, ketoprofen, etofenamate, phenylbutazone, andindomethacin. In embodiments, the immunosupressive agent may becytostatics such as alkylating agents, antimetabolites (e.g.,azathioprine, methotrexate), cytotoxic antibiotics, antibodies (e.g.,basiliximab, daclizumab, and muromonab), anti-immunophilins (e.g.,cyclosporine, tacrolimus, sirolimus), inteferons, opioids, TNF bindingproteins, mycophenolates, and small biological agents (e.g., fingolimod,myriocin).

In embodiments, the chimeric proteins (and/or additional agents)described herein, include derivatives that are modified, i.e., by thecovalent attachment of any type of molecule to the composition such thatcovalent attachment does not prevent the activity of the composition.For example, but not by way of limitation, derivatives includecomposition that have been modified by, inter a/ia, glycosylation,lipidation, acetylation, pegylation, phosphorylation, amidation,derivatization by known protecting/blocking groups, proteolyticcleavage, linkage to a cellular ligand or other protein, etc. Any ofnumerous chemical modifications can be carried out by known techniques,including, but not limited to specific chemical cleavage, acetylation,formylation, metabolic synthesis of turicamycin, etc. Additionally, thederivative can contain one or more non-classical amino acids. In stillembodiments, the chimeric proteins (and/or additional agents) describedherein further comprise a cytotoxic agent, comprising, in illustrativeembodiments, a toxin, a chemotherapeutic agent, a radioisotope, and anagent that causes apoptosis or cell death. Such agents may be conjugatedto a composition described herein.

The chimeric proteins (and/or additional agents) described herein maythus be modified post-translationally to add effector moieties such aschemical linkers, detectable moieties such as for example fluorescentdyes, enzymes, substrates, bioluminescent materials, radioactivematerials, and chemiluminescent moieties, or functional moieties such asfor example streptavidin, avidin, biotin, a cytotoxin, a cytotoxicagent, and radioactive materials.

Formulations

The chimeric proteins (and/or additional agents) described herein canpossess a sufficiently basic functional group, which can react with aninorganic or organic acid, or a carboxyl group, which can react with aninorganic or organic base, to form a pharmaceutically acceptable salt. Apharmaceutically acceptable acid addition salt is formed from apharmaceutically acceptable acid, as is well known in the art. Suchsalts include the pharmaceutically acceptable salts listed in, forexample, Journal of Pharmaceutical Science, 66, 2-19 (1977) and TheHandbook of Pharmaceutical Salts; Properties, Selection, and Use. P. H.Stahl and C. G. Wermuth (eds.), Verlag, Zurich (Switzerland) 2002, whichare hereby incorporated by reference in their entirety.

In embodiments, the compositions described herein are in the form of apharmaceutically acceptable salt.

Further, any chimeric protein (and/or additional agents) describedherein can be administered to a subject as a component of a compositionthat comprises a pharmaceutically acceptable carrier or vehicle. Suchcompositions can optionally comprise a suitable amount of apharmaceutically acceptable excipient so as to provide the form forproper administration. Pharmaceutical excipients can be liquids, such aswater and oils, including those of petroleum, animal, vegetable, orsynthetic origin, such as peanut oil, soybean oil, mineral oil, sesameoil and the like. The pharmaceutical excipients can be, for example,saline, gum acacia, gelatin, starch paste, talc, keratin, colloidalsilica, urea and the like. In addition, auxiliary, stabilizing,thickening, lubricating, and coloring agents can be used. In oneembodiment, the pharmaceutically acceptable excipients are sterile whenadministered to a subject. Water is a useful excipient when any agentdescribed herein is administered intravenously. Saline solutions andaqueous dextrose and glycerol solutions can also be employed as liquidexcipients, specifically for injectable solutions. Suitablepharmaceutical excipients also include starch, glucose, lactose,sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate,glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol,propylene, glycol, water, ethanol and the like. Any agent describedherein, if desired, can also comprise minor amounts of wetting oremulsifying agents, or pH buffering agents.

In embodiments, the compositions described herein are suspended in asaline buffer (including, without limitation TBS, PBS, and the like).

In embodiments, the chimeric proteins may by conjugated and/or fusedwith another agent to extend half-life or otherwise improvepharmacodynamic and pharmacokinetic properties. In embodiments, thechimeric proteins may be fused or conjugated with one or more of PEG,XTEN (e.g., as rPEG), polysialic acid (POLYXEN), albumin (e.g., humanserum albumin or HAS), elastin-like protein (ELP), PAS, HAP, GLK, CTP,transferrin, and the like. In embodiments, each of the individualchimeric proteins is fused to one or more of the agents described inBioDrugs (2015) 29:215-239, the entire contents of which are herebyincorporated by reference.

Administration, Dosing, and Treatment Regimens

The present invention includes the described chimeric protein (and/oradditional agents) in various formulations. Any chimeric protein (and/oradditional agents) described herein can take the form of solutions,suspensions, emulsion, drops, tablets, pills, pellets, capsules,capsules containing liquids, powders, sustained-release formulations,suppositories, emulsions, aerosols, sprays, suspensions, or any otherform suitable for use. DNA or RNA constructs encoding the proteinsequences may also be used. In one embodiment, the composition is in theform of a capsule (see, e.g., U.S. Pat. No. 5,698,155). Other examplesof suitable pharmaceutical excipients are described in Remington'sPharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro eds., 19th ed.1995), incorporated herein by reference.

Where necessary, the formulations comprising the chimeric protein(and/or additional agents) can also include a solubilizing agent. Also,the agents can be delivered with a suitable vehicle or delivery deviceas known in the art. Combination therapies outlined herein can beco-delivered in a single delivery vehicle or delivery device.Compositions for administration can optionally include a localanesthetic such as, for example, lignocaine to lessen pain at the siteof the injection.

The formulations comprising the chimeric protein (and/or additionalagents) of the present invention may conveniently be presented in unitdosage forms and may be prepared by any of the methods well known in theart of pharmacy. Such methods generally include the step of bringing thetherapeutic agents into association with a carrier, which constitutesone or more accessory ingredients. Typically, the formulations areprepared by uniformly and intimately bringing the therapeutic agent intoassociation with a liquid carrier, a finely divided solid carrier, orboth, and then, if necessary, shaping the product into dosage forms ofthe desired formulation (e.g., wet or dry granulation, powder blends,etc., followed by tableting using conventional methods known in the art)

In one embodiment, any chimeric protein (and/or additional agents)described herein is formulated in accordance with routine procedures asa composition adapted for a mode of administration described herein.

Routes of administration include, for example: intratumoral,intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous,intranasal, epidural, oral, sublingual, intranasal, intracerebral,intravaginal, transdermal, rectally, by inhalation, or topically,particularly to the ears, nose, eyes, or skin. In embodiments, theadministering is effected orally or by parenteral injection. In someinstances, administration results in the release of any agent describedherein into the bloodstream, or alternatively, the agent is administereddirectly to the site of active disease.

Any chimeric protein (and/or additional agents) described herein can beadministered orally. Such chimeric proteins (and/or additional agents)can also be administered by any other convenient route, for example, byintravenous infusion or bolus injection, by absorption throughepithelial or mucocutaneous linings (e.g., oral mucosa, rectal andintestinal mucosa, etc.) and can be administered together with anotherbiologically active agent. Administration can be systemic or local.Various delivery systems are known, e.g., encapsulation in liposomes,microparticles, microcapsules, capsules, etc., and can be used toadminister.

In specific embodiments, it may be desirable to administer locally tothe area in need of treatment. In one embodiment, for instance in thetreatment of cancer, the chimeric protein (and/or additional agents) areadministered in the tumor microenvironment (e.g., cells, molecules,extracellular matrix and/or blood vessels that surround and/or feed atumor cell, inclusive of, for example, tumor vasculature;tumor-infiltrating lymphocytes; fibroblast reticular cells; endothelialprogenitor cells (EPC); cancer-associated fibroblasts; pericytes; otherstromal cells; components of the extracellular matrix (ECM); dendriticcells; antigen presenting cells; T-cells; regulatory T cells;macrophages; neutrophils; and other immune cells located proximal to atumor) or lymph node and/or targeted to the tumor microenvironment orlymph node. In embodiments, for instance in the treatment of cancer, thechimeric protein (and/or additional agents) are administeredintratumorally.

In the embodiments, the present chimeric protein allows for a dualeffect that provides less side effects than are seen in conventionalimmunotherapy (e.g., treatments with one or more of OPDIVO, KEYTRUDA,YERVOY, and TECENTRIQ). For example, the present chimeric proteinsreduce or prevent commonly observed immune-related adverse events thataffect various tissues and organs including the skin, thegastrointestinal tract, the kidneys, peripheral and central nervoussystem, liver, lymph nodes, eyes, pancreas, and the endocrine system;such as hypophysitis, colitis, hepatitis, pneumonitis, rash, andrheumatic disease. Further, the present local administration, e.g.,intratumorally, obviate adverse event seen with standard systemicadministration, e.g., IV infusions, as are used with conventionalimmunotherapy (e.g., treatments with one or more of OPDIVO, KEYTRUDA,YERVOY, and TECENTRIQ).

Dosage forms suitable for parenteral administration (e.g., intravenous,intramuscular, intraperitoneal, subcutaneous and intra-articularinjection and infusion) include, for example, solutions, suspensions,dispersions, emulsions, and the like. They may also be manufactured inthe form of sterile solid compositions (e.g., lyophilized composition),which can be dissolved or suspended in sterile injectable mediumimmediately before use. They may contain, for example, suspending ordispersing agents known in the art.

The dosage of any chimeric protein (and/or additional agents) describedherein as well as the dosing schedule can depend on various parameters,including, but not limited to, the disease being treated, the subject'sgeneral health, and the administering physician's discretion.

Any chimeric protein described herein, can be administered prior to(e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeksbefore), concurrently with, or subsequent to (e.g., 5 minutes, 15minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks,4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after) theadministration of an additional agent, to a subject in need thereof. Inembodiments any chimeric protein and additional agent described hereinare administered 1 minute apart, 10 minutes apart, 30 minutes apart,less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hoursto 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hoursapart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to11 hours apart, 11 hours to 12 hours apart, 1 day apart, 2 days apart, 3days apart, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2weeks apart, 3 weeks apart, or 4 weeks apart.

In embodiments, the present invention relates to the co-administrationof the present chimeric protein comprising the extracellular domain ofcolony stimulating factor 1 receptor (CSF1R) and another chimericprotein which induces an adaptive immune response. In such embodiments,the present chimeric protein may be administered before, concurrentlywith, or subsequent to administration of the chimeric protein whichinduces an adaptive immune response. For example, the chimeric proteinsmay be administered 1 minute apart, 10 minutes apart, 30 minutes apart,less than 1 hour apart, 1 hour apart, 1 hour to 2 hours apart, 2 hoursto 3 hours apart, 3 hours to 4 hours apart, 4 hours to 5 hours apart, 5hours to 6 hours apart, 6 hours to 7 hours apart, 7 hours to 8 hoursapart, 8 hours to 9 hours apart, 9 hours to 10 hours apart, 10 hours to11 hours apart, 11 hours to 12 hours apart, 1 day apart, 2 days apart, 3days part, 4 days apart, 5 days apart, 6 days apart, 1 week apart, 2weeks apart, 3 weeks apart, or 4 weeks apart. In an exemplaryembodiment, the present chimeric protein comprising the extracellulardomain of CSF1R and the chimeric protein which induces an adaptiveimmune response are administered 1 week apart, or administered onalternate weeks (i.e., administration of the present chimeric proteincomprising the extracellular domain of CSF1R is followed 1 week laterwith administration of the chimeric protein inducing an adaptive immuneresponse and so forth).

The dosage of any chimeric protein (and/or additional agents) describedherein can depend on several factors including the severity of thecondition, whether the condition is to be treated or prevented, and theage, weight, and health of the subject to be treated. Additionally,pharmacogenomic (the effect of genotype on the pharmacokinetic,pharmacodynamic or efficacy profile of a therapeutic) information abouta particular subject may affect dosage used. Furthermore, the exactindividual dosages can be adjusted somewhat depending on a variety offactors, including the specific combination of the agents beingadministered, the time of administration, the route of administration,the nature of the formulation, the rate of excretion, the particulardisease being treated, the severity of the disorder, and the anatomicallocation of the disorder. Some variations in the dosage can be expected.For administration of any chimeric protein (and/or additional agents)described herein by parenteral injection, the dosage may be about 0.1 mgto about 250 mg per day, about 1 mg to about 20 mg per day, or about 3mg to about 5 mg per day. Generally, when orally or parenterallyadministered, the dosage of any agent described herein may be about 0.1mg to about 1500 mg per day, or about 0.5 mg to about 10 mg per day, orabout 0.5 mg to about 5 mg per day, or about 200 to about 1,200 mg perday (e.g., about 200 mg, about 300 mg, about 400 mg, about 500 mg, about600 mg, about 700 mg, about 800 mg, about 900 mg, about 1,000 mg, about1,100 mg, about 1,200 mg per day).

In embodiments, administration of the chimeric protein (and/oradditional agents) described herein is by parenteral injection at adosage of about 0.1 mg to about 1500 mg per treatment, or about 0.5 mgto about 10 mg per treatment, or about 0.5 mg to about 5 mg pertreatment, or about 200 to about 1,200 mg per treatment (e.g., about 200mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700mg, about 800 mg, about 900 mg, about 1,000 mg, about 1,100 mg, about1,200 mg per treatment).

In embodiments, a suitable dosage of the chimeric protein (and/oradditional agents) is in a range of about 0.01 mg/kg to about 100 mg/kgof body weight ,or about 0.01 mg/kg to about 10 mg/kg of body weight ofthe subject, for example, about 0.01 mg/kg, about 0.02 mg/kg, about 0.03mg/kg, about 0.04 mg/kg, about 0.05 mg/kg, about 0.06 mg/kg, about 0.07mg/kg, about 0.08 mg/kg, about 0.09 mg/kg, about 0.1 mg/kg, about 0.2mg/kg, about 0.3 mg/kg, about 0.4 mg/kg, about 0.5 mg/kg, about 0.6mg/kg, about 0.7 mg/kg, about 0.8 mg/kg, about 0.9 mg/kg, about 1 mg/kg,about 1.1 mg/kg, about 1.2 mg/kg, about 1.3 mg/kg, about 1.4 mg/kg,about 1.5 mg/kg, about 1.6 mg/kg, about 1.7 mg/kg, about 1.8 mg/kg, 1.9mg/kg, about 2 mg/kg, about 3 mg/kg, about 4 mg/kg, about 5 mg/kg, about6 mg/kg, about 7 mg/kg, about 8 mg/kg, about 9 mg/kg, about 10 mg/kgbody weight, inclusive of all values and ranges therebetween. In anembodiment, delivery can be in a vesicle, in particular a liposome (seeLanger, 1990, Science 249:1527-1533; Treat et al., in Liposomes in theTherapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler(eds.), Liss, New York, pp. 353-365 (1989).

Any chimeric protein (and/or additional agents) described herein can beadministered by controlled-release or sustained-release means or bydelivery devices that are well known to those of ordinary skill in theart. Examples include, but are not limited to, those described in U.S.Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719;5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476;5,354,556; and 5,733,556, each of which is incorporated herein byreference in its entirety. Such dosage forms can be useful for providingcontrolled- or sustained-release of one or more active ingredientsusing, for example, hydropropylmethyl cellulose, other polymer matrices,gels, permeable membranes, osmotic systems, multilayer coatings,microparticles, liposomes, microspheres, or a combination thereof toprovide the desired release profile in varying proportions. Controlled-or sustained-release of an active ingredient can be stimulated byvarious conditions, including but not limited to, changes in pH, changesin temperature, stimulation by an appropriate wavelength of light,concentration or availability of enzymes, concentration or availabilityof water, or other physiological conditions or compounds.

In an embodiment, polymeric materials can be used (see MedicalApplications of Controlled Release, Langer and Wise (eds.), CRC Pres.,Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug ProductDesign and Performance, Smolen and Ball (eds.), Wiley, N.Y. (1984);Ranger and Peppas, 1983, J. Macromol. Sci. Rev. Macromol. Chem. 23:61;see also Levy et al., 1985, Science 228:190; During et al., 1989, Ann.Neurol. 25:351; Howard et al., 1989, J. Neurosurg. 71:105).

In an embodiment, a controlled-release system can be placed in proximityof the target area to be treated, thus requiring only a fraction of thesystemic dose (see, e.g., Goodson, in Medical Applications of ControlledRelease, supra, vol. 2, pp. 115-138 (1984)). Other controlled-releasesystems discussed in the review by Langer, 1990, Science 249:1527-1533)may be used.

Administration of any chimeric protein (and/or additional agents)described herein can, independently, be one to four times daily or oneto four times per month or one to six times per year or once every two,three, four or five years. Administration can be for the duration of oneday or one month, two months, three months, six months, one year, twoyears, three years, and may even be for the life of the subject.

The dosage regimen utilizing any chimeric protein (and/or additionalagents) described herein can be selected in accordance with a variety offactors including type, species, age, weight, sex and medical conditionof the subject; the severity of the condition to be treated; the routeof administration; the renal or hepatic function of the subject; thepharmacogenomic makeup of the individual; and the specific compound ofthe invention employed. Any chimeric protein (and/or additional agents)described herein can be administered in a single daily dose, or thetotal daily dosage can be administered in divided doses of two, three orfour times daily. Furthermore, any chimeric protein (and/or additionalagents) described herein can be administered continuously rather thanintermittently throughout the dosage regimen.

Cells and Nucleic Acids

In embodiments, the present invention provides an expression vector,comprising a nucleic acid encoding the chimeric protein describedherein. In embodiments, the expression vector comprises DNA or RNA. Inembodiments, the expression vector is a mammalian expression vector.

Both prokaryotic and eukaryotic vectors can be used for expression ofthe chimeric protein. Prokaryotic vectors include constructs based on E.coli sequences (see, e.g., Makrides, Microbiol Rev 1996, 60:512-538).Non-limiting examples of regulatory regions that can be used forexpression in E. coli include lac, trp, Ipp, phoA, recA, tac, T3, T7 andλP_(L). Non-limiting examples of prokaryotic expression vectors mayinclude the λgt vector series such as λgt11 (Huynh et al., in “DNACloning Techniques, Vol. I: A Practical Approach,” 1984, (D. Glover,ed.), pp. 49-78, IRL Press, Oxford), and the pET vector series (Studieret al., Methods Enzymol 1990, 185:60-89). Prokaryotic host-vectorsystems cannot perform much of the post-translational processing ofmammalian cells, however. Thus, eukaryotic host-vector systems may beparticularly useful. A variety of regulatory regions can be used forexpression of the chimeric proteins in mammalian host cells. Forexample, the SV40 early and late promoters, the cytomegalovirus (CMV)immediate early promoter, and the Rous sarcoma virus long terminalrepeat (RSV-LTR) promoter can be used. Inducible promoters that may beuseful in mammalian cells include, without limitation, promotersassociated with the metallothionein II gene, mouse mammary tumor virusglucocorticoid responsive long terminal repeats (MMTV-LTR), theβ-interferon gene, and the hsp70 gene (see, Williams et al., Cancer Res1989, 49:2735-42; and Taylor et al., Mol Cell Biol 1990, 10:165-75).Heat shock promoters or stress promoters also may be advantageous fordriving expression of the fusion proteins in recombinant host cells.

In embodiments, expression vectors of the invention comprise a nucleicacid encoding the chimeric proteins (and/or additional agents), or acomplement thereof, operably linked to an expression control region, orcomplement thereof, that is functional in a mammalian cell. Theexpression control region is capable of driving expression of theoperably linked blocking and/or stimulating agent encoding nucleic acidsuch that the blocking and/or stimulating agent is produced in a humancell transformed with the expression vector.

Expression control regions are regulatory polynucleotides (sometimesreferred to herein as elements), such as promoters and enhancers, thatinfluence expression of an operably linked nucleic acid. An expressioncontrol region of an expression vector of the invention is capable ofexpressing operably linked encoding nucleic acid in a human cell. Inembodiments, the cell is a tumor cell. In an embodiment, the cell is anon-tumor cell. In embodiments, the expression control region confersregulatable expression to an operably linked nucleic acid. A signal(sometimes referred to as a stimulus) can increase or decreaseexpression of a nucleic acid operably linked to such an expressioncontrol region. Such expression control regions that increase expressionin response to a signal are often referred to as inducible. Suchexpression control regions that decrease expression in response to asignal are often referred to as repressible. Typically, the amount ofincrease or decrease conferred by such elements is proportional to theamount of signal present; the greater the amount of signal, the greaterthe increase or decrease in expression.

In embodiments, the present invention contemplates the use of induciblepromoters capable of effecting high level of expression transiently inresponse to a cue. For example, when in the proximity of a tumor cell, acell transformed with an expression vector for the chimeric protein(and/or additional agents) comprising such an expression controlsequence is induced to transiently produce a high level of the agent byexposing the transformed cell to an appropriate cue. Illustrativeinducible expression control regions include those comprising aninducible promoter that is stimulated with a cue such as a smallmolecule chemical compound. Particular examples can be found, forexample, in U.S. Pat. Nos. 5,989,910, 5,935,934, 6,015,709, and6,004,941, each of which is incorporated herein by reference in itsentirety.

Expression control regions and locus control regions include full-lengthpromoter sequences, such as native promoter and enhancer elements, aswell as subsequences or polynucleotide variants which retain all or partof full-length or non-variant function. As used herein, the term“functional” and grammatical variants thereof, when used in reference toa nucleic acid sequence, subsequence or fragment, means that thesequence has one or more functions of native nucleic acid sequence(e.g., non-variant or unmodified sequence).

As used herein, “operable linkage” refers to a physical juxtaposition ofthe components so described as to permit them to function in theirintended manner. In the example of an expression control element inoperable linkage with a nucleic acid, the relationship is such that thecontrol element modulates expression of the nucleic acid. Typically, anexpression control region that modulates transcription is juxtaposednear the 5′ end of the transcribed nucleic acid (i.e., “upstream”).Expression control regions can also be located at the 3′ end of thetranscribed sequence (i.e., “downstream”) or within the transcript(e.g., in an intron). Expression control elements can be located at adistance away from the transcribed sequence (e.g., 100 to 500, 500 to1000, 2000 to 5000, or more nucleotides from the nucleic acid). Aspecific example of an expression control element is a promoter, whichis usually located 5′ of the transcribed sequence. Another example of anexpression control element is an enhancer, which can be located 5′ or 3′of the transcribed sequence, or within the transcribed sequence.

Expression systems functional in human cells are well known in the art,and include viral systems. Generally, a promoter functional in a humancell is any DNA sequence capable of binding mammalian RNA polymerase andinitiating the downstream (3′) transcription of a coding sequence intomRNA. A promoter will have a transcription initiating region, which isusually placed proximal to the 5′ end of the coding sequence, andtypically a TATA box located 25-30 base pairs upstream of thetranscription initiation site. The TATA box is thought to direct RNApolymerase II to begin RNA synthesis at the correct site. A promoterwill also typically contain an upstream promoter element (enhancerelement), typically located within 100 to 200 base pairs upstream of theTATA box. An upstream promoter element determines the rate at whichtranscription is initiated and can act in either orientation. Ofparticular use as promoters are the promoters from mammalian viralgenes, since the viral genes are often highly expressed and have a broadhost range. Examples include the SV40 early promoter, mouse mammarytumor virus LTR promoter, adenovirus major late promoter, herpes simplexvirus promoter, and the CMV promoter.

Typically, transcription termination and polyadenylation sequencesrecognized by mammalian cells are regulatory regions located 3′ to thetranslation stop codon and thus, together with the promoter elements,flank the coding sequence. The 3′ terminus of the mature mRNA is formedby site-specific post-translational cleavage and polyadenylation.Examples of transcription terminator and polyadenylation signals includethose derived from SV40. Introns may also be included in expressionconstructs.

There are a variety of techniques available for introducing nucleicacids into viable cells. Techniques suitable for the transfer of nucleicacid into mammalian cells in vitro include the use of liposomes,electroporation, microinjection, cell fusion, polymer-based systems,DEAE-dextran, viral transduction, the calcium phosphate precipitationmethod, etc. For in vivo gene transfer, a number of techniques andreagents may also be used, including liposomes; natural polymer-baseddelivery vehicles, such as chitosan and gelatin; viral vectors are alsosuitable for in vivo transduction. In some situations, it is desirableto provide a targeting agent, such as an antibody or ligand specific fora tumor cell surface membrane protein. Where liposomes are employed,proteins which bind to a cell surface membrane protein associated withendocytosis may be used for targeting and/or to facilitate uptake, e.g.,capsid proteins or fragments thereof tropic for a particular cell type,antibodies for proteins which undergo internalization in cycling,proteins that target intracellular localization and enhanceintracellular half-life. The technique of receptor-mediated endocytosisis described, for example, by Wu et al, J. Biol. Chem. 262, 4429-4432(1987); and Wagner et al, Proc. Natl. Acad. Sci. USA 87, 3410-3414(1990).

Where appropriate, gene delivery agents such as, e.g., integrationsequences can also be employed. Numerous integration sequences are knownin the art (see, e.g., Nunes-Duby et al., Nucleic Acids Res. 26:391-406,1998; Sadwoski, J. Bacteriol., 165:341-357, 1986; Bestor, Cell,122(3):322-325, 2005; Plasterk et al, TIG 15:326-332, 1999; Kootstra etal, Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). These includerecombinases and transposases. Examples include Cre (Sternberg andHamilton, J. Mol. Biol., 150:467-486, 1981), lambda (Nash, Nature, 247,543-545, 1974), Flp (Broach, et al., Cell, 29:227-234, 1982), R(Matsuzaki, et al., J. Bacteriology, 172:610-618, 1990), cpC31 (see,e.g., Groth et al, J. Mol. Biol. 335:667-678, 2004), sleeping beauty,transposases of the mariner family (Plasterk et al, supra), andcomponents for integrating viruses such as AAV, retroviruses, andantiviruses having components that provide for virus integration such asthe LTR sequences of retroviruses or lentivirus and the ITR sequences ofAAV (Kootstra et al, Ann. Rev. Pharm. Toxicol., 43:413-439, 2003). Inaddition, direct and targeted genetic integration strategies may be usedto insert nucleic acid sequences encoding the chimeric proteinsincluding CRISPR/CAS9, zinc finger, TALEN, and meganuclease gene-editingtechnologies.

In aspects, the invention provides expression vectors for the expressionof the chimeric proteins (and/or additional agents) that are viralvectors. Many viral vectors useful for gene therapy are known (see,e.g., Lundstrom, Trends Biotechnol., 21: 1 17, 122, 2003. Illustrativeviral vectors include those selected from Antiviruses (LV), retroviruses(RV), adenoviruses (AV), adeno-associated viruses (AAV), and a viruses,though other viral vectors may also be used. For in vivo uses, viralvectors that do not integrate into the host genome are suitable for use,such as a viruses and adenoviruses. Illustrative types of a virusesinclude Sindbis virus, Venezuelan equine encephalitis (VEE) virus, andSemliki Forest virus (SFV). For in vitro uses, viral vectors thatintegrate into the host genome are suitable, such as retroviruses, AAV,and Antiviruses. In one embodiment, the invention provides methods oftransducing a human cell in vivo, comprising contacting a solid tumor invivo with a viral vector of the invention.

In embodiments, the present invention provides a host cell, comprisingthe expression vector comprising the chimeric protein described herein.

Expression vectors can be introduced into host cells for producing thepresent chimeric proteins. Cells may be cultured in vitro or geneticallyengineered, for example. Useful mammalian host cells include, withoutlimitation, cells derived from humans, monkeys, and rodents (see, forexample, Kriegler in “Gene Transfer and Expression: A LaboratoryManual,” 1990, New York, Freeman & Co.). These include monkey kidneycell lines transformed by SV40 (e.g., COS-7, ATCC CRL 1651); humanembryonic kidney lines (e.g., 293, 293-EBNA, or 293 cells subcloned forgrowth in suspension culture, Graham et al, J Gen Virol 1977, 36:59);baby hamster kidney cells (e.g., BHK, ATCC CCL 10); Chinese hamsterovary-cells-DHFR (e.g., CHO, Urlaub and Chasin, Proc Natl Acad Sci USA1980, 77:4216); DG44 CHO cells, CHO-K1 cells, mouse sertoli cells(Mather, Biol Reprod 1980, 23:243-251); mouse fibroblast cells (e.g.,NIH-3T3), monkey kidney cells (e.g., CV1 ATCC CCL 70); African greenmonkey kidney cells. (e.g., VERO-76, ATCC CRL-1587); human cervicalcarcinoma cells (e.g., HELA, ATCC CCL 2); canine kidney cells (e.g.,MDCK, ATCC CCL 34); buffalo rat liver cells (e.g., BRL 3A, ATCC CRL1442); human lung cells (e.g., W138, ATCC CCL 75); human liver cells(e.g., Hep G2, HB 8065); and mouse mammary tumor cells (e.g., MMT060562, ATCC CCL51). Illustrative cancer cell types for expressing thefusion proteins described herein include mouse fibroblast cell line,NIH3T3, mouse Lewis lung carcinoma cell line, LLC, mouse mastocytomacell line, P815, mouse lymphoma cell line, EL4 and its ovalbumintransfectant, E.G7, mouse melanoma cell line, B16F10, mouse fibrosarcomacell line, MC57, and human small cell lung carcinoma cell lines, SCLC#2and SCLC#7.

Host cells can be obtained from normal or affected subjects, includinghealthy humans, cancer patients, and patients with an infectiousdisease, private laboratory deposits, public culture collections such asthe American Type Culture Collection, or from commercial suppliers.

Cells that can be used for production of the present chimeric proteinsin vitro, ex vivo, and/or in vivo include, without limitation,epithelial cells, endothelial cells, keratinocytes, fibroblasts, musclecells, hepatocytes; blood cells such as T lymphocytes, B lymphocytes,monocytes, macrophages, neutrophils, eosinophils, megakaryocytes,granulocytes; various stem or progenitor cells, in particularhematopoietic stem or progenitor cells (e.g., as obtained from bonemarrow), umbilical cord blood, peripheral blood, fetal liver, etc. Thechoice of cell type depends on the type of tumor or infectious diseasebeing treated or prevented, and can be determined by one of skill in theart.

Subjects and/or Animals

In embodiments, the subject and/or animal is a mammal, e.g., a human,mouse, rat, guinea pig, dog, cat, horse, cow, pig, rabbit, sheep, ornon-human primate, such as a monkey, chimpanzee, or baboon. Inembodiments, the subject and/or animal is a non-mammal, such, forexample, a zebrafish. In embodiments, the subject and/or animal maycomprise fluorescently-tagged cells (e.g., with GFP). In embodiments,the subject and/or animal is a transgenic animal comprising afluorescent cell.

In embodiments, the subject and/or animal is a human. In embodiments,the human is a pediatric human. In embodiments, the human is an adulthuman. In embodiments, the human is a geriatric human. In embodiments,the human may be referred to as a patient.

In embodiments, the human has an age in a range of from about 0 monthsto about 6 months old, from about 6 to about 12 months old, from about 6to about 18 months old, from about 18 to about 36 months old, from about1 to about 5 years old, from about 5 to about 10 years old, from about10 to about 15 years old, from about 15 to about 20 years old, fromabout 20 to about 25 years old, from about 25 to about 30 years old,from about 30 to about 35 years old, from about 35 to about 40 yearsold, from about 40 to about 45 years old, from about 45 to about 50years old, from about 50 to about 55 years old, from about 55 to about60 years old, from about 60 to about 65 years old, from about 65 toabout 70 years old, from about 70 to about 75 years old, from about 75to about 80 years old, from about 80 to about 85 years old, from about85 to about 90 years old, from about 90 to about 95 years old or fromabout 95 to about 100 years old.

In embodiments, the subject is a non-human animal, and therefore theinvention pertains to veterinary use. In a specific embodiment, thenon-human animal is a household pet. In another specific embodiment, thenon-human animal is a livestock animal.

Kits

The invention provides kits that can simplify the administration of anyagent described herein. An illustrative kit of the invention comprisesany composition described herein in unit dosage form. In one embodiment,the unit dosage form is a container, such as a pre-filled syringe, whichcan be sterile, containing any agent described herein and apharmaceutically acceptable carrier, diluent, excipient, or vehicle. Thekit can further comprise a label or printed instructions instructing theuse of any agent described herein. The kit may also include a lidspeculum, topical anesthetic, and a cleaning agent for theadministration location. The kit can also further comprise one or moreadditional agent described herein. In one embodiment, the kit comprisesa container containing an effective amount of a composition of theinvention and an effective amount of another composition, such thosedescribed herein.

Any aspect or embodiment described herein can be combined with any otheraspect or embodiment as disclosed herein.

The invention will be further described in the following examples, whichdo not limit the scope of the invention described in the claims.

EXAMPLES

Example 1

Predicted Mechanism of Action and In Silico Predicted Structure ofMonomeric CSF1R-Fc-CD40L Chimeric Protein

FIG. 1A shows a schematic representation of the expected mechanism ofaction of a CSF1R-Fc-CD40L chimeric protein. The CSF1R domain binds CSF1and/or IL-34 to provide a ‘sink effect’ and prevent CSF1 and/or IL-34from binding CSF1R on the surface of antigen presenting cells, therebyblocking an immune inhibition signal. Contemporaneously, the CD40Ldomain of the chimeric protein binds CD40 on the surface of antigenpresenting cells, thereby providing an immune activation signal. The neteffect of these two events increases an immune response by blocking aninhibitory signal (via IL-34 and/or CSF1) and providing an activatingsignal via CD40.

FIG. 1B shows a synapse that has formed by a chimeric protein between atumor cell and a T cell.

FIG. 1C shows an in silico structure prediction of the monomericCSF1R-Fc-CD40L chimeric protein (SL-115154) having 947 amino acidresidues (SEQ ID NO: 5), with a p-value 1.69×10⁻²⁹. The molecular weightof the monomeric protein was predicted to be 105.4 kDa. A structure ofthe chimeric protein is provided in FIG. 1A.

Specifically, the structure prediction revealed that 33 amino acidpositions (3%) may be disordered. Secondary structure prediction of theentire sequence of the chimeric protein showed that the protein has thecomposition of 2% α-helix (H), 51% β-sheet (E), and 45% coil (C). TheGDT (global distance test) and uGDT (un-normalized GDT) for the absoluteglobal quality were also calculated for the chimeric protein to give anoverall uGDT(GDT) of 738 (78). The three-state prediction for solventaccessibility of the protein residues were 33% exposed (E), 46%intermediate (M), and 19% buried (B).

Example 2 Characterization of CSF1R-Fc-CD40L Chimeric Protein

A human CSF1R-Fc-CD40L (also referred to as CD115-Fc-CD40L herein)chimeric protein was constructed as described above in the DetailedDescription and in U.S. 62/464,002, the contents of which are herebyincorporated by reference in its entirety. The chimeric protein wascharacterized by performing a Western blot analysis against eachindividual domain of the chimeric protein, i.e., via anti-CSF1R,anti-Fc, and anti-CD40L antibodies.

The Western blots indicated the presence of an oligomeric species(possibly a dimer), with an apparent molecular weight of approximately240 kDa, in the non-reduced lanes (FIG. 2, lane 2 in each blot), whichwas reduced to a glycosylated monomeric band in the presence of thereducing agent, β-mercaptoethanol (FIG. 2, lane 3 in each blot). Asshown in FIG. 2, lane 4 in each blot, the chimeric protein ran as amonomer at the predicted molecular weight of approximately 105 kDa inthe presence of both a reducing agent (β-mercaptoethanol) and anendoglycosidase (PNGase).

Example 3 Characterization of the Binding Affinity of the DifferentDomains of the CSF1R-Fc-CD40L Chimeric Protein Using ELISA

Enzyme-Linked Immunosorbent assay (ELISA) assays were developed todemonstrate the binding affinity of the different domains of thehCSF1R-Fc-CD40L (also referred to as CD115-Fc-CD40L herein) to theirrespective binding partners (i.e., CSF1, hlgG, or CD40). Specifically,the Fc portion of the chimeric protein was detected by capturing to aplate-bound human IgG and detecting via an HRP-conjugated anti-human IgGantibody (upper left quadrant of FIG. 3). The CSF1R domain of thehCSF1R-Fc-CD40L chimeric protein was detected by capturing to aplate-bound recombinant human CSF1 protein and detecting via aHRP-conjugated anti-human IgG antibody (upper right quadrant of FIG. 3).The CD40L domain of the chimeric protein was detected by capturing to aplate-bound recombinant human CD40 protein and detecting via aCD40L-specific antibody (bottom left quadrant of FIG. 3). Finally,contemporaneous binding to both CSF1 and CD40 was demonstrated using adual ELISA format in which recombinant CD40 was used to captureCSF1R-Fc-CD40L and recombinant CSF1 was used to detect CSF1R-Fc-CD40L(bottom right portion of FIG. 3).

Example 4 Characterization of the Ex Vivo Cell Binding Affinity of theCSF1R-Fc-CD40L Chimeric Protein

Cell binding assays were performed to demonstrate the binding affinityof the different domains of the mCSF1R-Fc-CD40L chimeric protein towardstheir respective binding partners on the surface of a mammalian cellmembrane.

For cell binding assays, immortalized cell lines were engineered tostably express CD40 (Jurkat/CD40). Increasing concentrations of theCSF1R-Fc-CD40L chimeric protein were incubated with the over-expressing(Jurkat/CD40) cell line for 2 hours. Cells were collected, washed, andstained with antibodies for the detection of chimeric protein binding byflow cytometry.

As shown in FIG. 4, the CSF1R-Fc-CD40L chimeric protein bound to CD40present on the cell surface in a concentration-dependent manner and withlow nM affinity. Specifically, as shown in FIG. 4, the cell bindingassay demonstrated that CSF1R-Fc-CD40L binds to CD40 and with anaffinity of about 77 nM (according to the EC₅₀ calculation).

Example 5 Characterization of the Binding Affinity of the CSF1R-Fc-CD40LChimeric Protein by Surface Plasmon Resonance (SPR) and Bio-LayerSurface Interferometry

The binding affinity of the different domains of the hCSF1R-Fc-CD40Lchimeric protein was measured by the surface plasmon resonance (SPR)using the BioRad ProteOn XPR 360 system. Specifically, the affinity ofthe chimeric protein for human CSF1 and CD40 was determined and comparedto recombinant control proteins, and the results are shown in the Tablebelow:

KA KD KD SAMPLE (ON-RATE; 1/MS) (OFF-RATE; 1/S) (BINDING; M) BINDING TO:CSF CSF1R-Fc 1.22E+6 3.35E−4 .275 nM CSF1R-Fc-CD40L 5.70E+4 7.30E−6 .128nM CD40 CD40L-Fc NA NA NA CSF1R-Fc-CD40L 1.28E+4 6.74E−6 .527 nM

It was determined that the hCSF1R-Fc-CD40L chimeric protein binds toCSF1 and CD40 with high affinity. In particular, it was noted that theoff-rates of the hCSF1R-Fc-CD40L chimeric protein are much slower thanthe control proteins (i.e., CSF1R-Fc and CD40L-Fc). For example, theoff-rate of the chimeric protein from CSF1 was 45.9 fold slower than theCSF1R-Fc protein.

In addition, the binding affinity of each domain of CSF1R-Fc-CD40L wasmeasured using an Octet system based on Bio-Layer Surface Interferometry(FIG. 5A to FIG. 5F). These results further confirm high affinitybinding of the CSF1R-Fc-CD40L chimeric protein to each binding partner.

Example 6 Binding Affinity to Both CSF1R Ligands

CSF1R has been reported to bind two ligands: CSF1 and IL-34. Thus, itwas desirable to demonstrate that CSF1R-Fc-CD40L is capable of bindingboth CSF1 and IL-34. This was tested using bio-layer surfaceinterferometry (Octet), with results shown in FIG. 6. The binding ofCSF1R-Fc-CD40L to CSF1 and IL-34 was indistinguishable; thus, the curvesare virtually overlayed on top of one another.

Example 7 Characterization of Murine CSF1R-Fc-CD40L Chimeric Protein

A murine CSF1R-Fc-CD40L (also referred to as mCSF1R-Fc-CD40L in thepresent disclosure) chimeric protein was constructed as described abovein the Detailed Description and in U.S. 62/464,002, the contents ofwhich are hereby incorporated by reference in its entirety. The chimericprotein was characterized by performing a Western blot analysis againsteach individual domain of the chimeric protein, i.e., via α-CSF1R, α-Fc,and α-CD40L antibodies.

The Western blots indicated the presence of an oligomeric species(possibly a dimer), with an apparent molecular weight of approximately240 kDa in the non-reduced lanes (FIG. 7A, lane 2 in each blot), whichwas reduced to a glycosylated monomeric band in the presence of thereducing agent, β-mercaptoethanol (FIG. 7A, lane 3 in each blot). Asshown in FIG. 7A, lane 4 in each blot, the chimeric protein ran as amonomer at the predicted molecular weight of approximately 105 kDa inthe presence of both a reducing agent (β-mercaptoethanol) and anendoglycosidase (PNGase).

Enzyme-Linked Immunosorbent assay (ELISA) assays were developed todemonstrate the binding affinity of the different domains of themCSF1R-Fc-CD40L to their respective binding partners (i.e., CSF1, mIgG,or CD40). Specifically, the Fc portion of the chimeric protein wasdetected by capturing to a plate-bound mouse IgG and detecting via anHRP-conjugated anti-mouse IgG antibody (middle graph of FIG. 7B). TheCSF1R domain of the mCSF1R-Fc-CD40L chimeric protein was detected bycapturing to a plate-bound recombinant murine CSF1 protein and detectingvia a HRP-conjugated anti-mouse IgG antibody (left graph of FIG. 7B).The CD40L domain of the chimeric protein was detected by capturing to aplate-bound recombinant mouse CD40 protein and detecting via aCD40L-specific antibody (right graph of FIG. 7B).

As shown in FIG. 7B, the different domains of the hCSF1R-Fc-CD40Lchimeric protein effectively interacted with their respective bindingpartners with high affinity. Nevertheless, it was observed that in ELISAassays, using the central Fc region to detect chimeric proteins tendedto underestimate the actual protein content in a sample. Therefore, lowlevel of the hCSF1R-Fc-CD40L chimeric protein was detected compared tostandard in this assay.

Example 8 Characterization of the Ex Vivo Cell Binding Affinity of theMurine CSF1R-Fc-CD40L Chimeric Protein

Cell binding assays were performed to demonstrate the binding affinityof the different domains of the mCSF1R-Fc-CD40L chimeric protein towardstheir respective binding partners on the surface of a mammalian cellmembrane.

For cell binding assays, immortalized cell lines were engineered tostably express CD40 (CHOK1/CD40). Increasing concentrations of themurine CSF1R-Fc-CD40L chimeric protein were incubated with theover-expressing (CHOK1/CD40) cell line for 2 hours. Cells werecollected, washed, and stained with antibodies for the detection ofchimeric protein binding by flow cytometry.

As shown in FIG. 8, the murine CSF1R-Fc-CD40L chimeric protein bound toCD40 present on the cell surface in a concentration-dependent manner andwith low nM affinity. Specifically, as shown in FIG. 8, the cell bindingassay demonstrated that CSF1R-Fc-CD40L bound to CD40 with an affinity of91.1 nM (according to the EC₅₀ calculation). As a negative control,there was no detectable binding to the parental (non-CD40 expressing)CHOK1 cell line.

Example 9 Induction of CD40 Signaling in Vitro

Human CD40 is a homo-trimeric receptor that, when activated, leads toinduction of a signaling cascade which involves both NF-κB and NIKactivation. FIG. 9 shows example data from an in vitro NF-κB/NIKsignaling assay using the human CSF1R-Fc-CD40L chimeric protein. U20Scells from the DiscoverX NIK signaling assay were cultured with atitration of either a commercially-available single-sided CD40L-Fc,single-sided single-sided CSF1R-Fc, or a CD40 agonist antibody, or thehuman CSF1R-Fc-CD40L chimeric protein. The relative luciferase units(RLU) indicate the relative strength of NF-κB/NIK signaling activatedfollowing treatment with the indicated regimens. hCSF1R-Fc-CD40L isshown to have strongly activated signaling via NF-κB and NIK, to acomparable degree as a CD40L-Fc chimeric protein. The CD40 agonistantibody did not stimulate CD40 activation in this assay because theantibody requires Fc receptor cross-linking in order to facilitateappropriate clustering of the CD40 receptor.

Example 10 Functional Assays of the CSF1R-Fc-CD40L Chimeric Protein

CSF1R (also known as CD115) has been identified as an emergent immunecheckpoint due to its role in binding to CSF1 and/or IL-34 within thetumor microenvironment. As shown in FIG. 1A, binding of CSF1R to eitherof these two ligands stimulates immune suppression through variousmechanisms, including the induction of myeloid derived suppressor cells.Without wishing to be bound by theory, it is believed that theCSF1R-Fc-CD40L chimeric protein may contemporaneously act as a cytokinetrap for CSF1/IL-34 and stimulates macrophages and antigen presentingcells via CD40 thereby generating potent anti-tumor immunity.

Two functional assays were developed to characterize the functionalactivity of the mCSF1R-Fc-CD40L chimeric protein.

The first assay is an in vivo trap/sink assay for assessing the abilityof the mCSF1R-Fc-CD40L chimeric protein to bind and reduce serum levelsof soluble CSF1. Specifically, non-tumor-bearing mice were injected witha single dose of anti-CSF1R antibody (also known as anti-CD115 antibody)on day 0. On day 2, mice were either left untreated, or injected with asingle dose of the CSF1R-Fc-CD40L chimeric protein. Blood serum wascollected on day 2 before injection of the chimeric protein and on day 3after treatment with the chimeric protein. ELISA assays of murine CSF1were performed on the serum. As shown in FIG. 10A, the mCSF1R-Fc-CD40Lchimeric protein was able to bind and significantly reduce the serumlevels of soluble CSF1 thus eliminating its detection by ELISA.

The second assay involved in vivo immune profiling of tumor-bearing mice13 days after treatment with the mCSF1R-Fc-CD40L chimeric protein.Specifically, the levels of IL15Rα+ cells in the spleen and lymph nodeswere analyzed as a readout for immune activation by the chimeric protein(particularly by the CD40L portion of the chimeric protein).Tumor-bearing mice were treated with two doses of 150 μg of themCSF1R-Fc-CD40L chimeric protein on days 5 and 7 after initial tumorinoculation. On day 13, a cohort of mice was sacrificed and theirspleens and lymph nodes were removed and dissociated for flow cytometryanalysis of IL15Rα. Levels of IL15Rα+ cells in the spleen and lymphnodes were determined as shown in FIG. 10B. Consistent with a knownmechanism of CD40L function, mice treated with the chimeric proteindisplayed an increase in IL15Rα in the spleen and lymph nodes comparedto untreated mice, strongly suggesting that the chimeric proteinstimulated immune activation via the CD40/CD40L pathway.

Example 11 Characterization of the in Vivo Anti-Tumor Activities of theCSF1R-Fc-CD40L Chimeric Protein

The in vivo anti-tumor activity of the mCSF1R-Fc-CD40L chimeric proteinwas analyzed using the CT26 mouse colorectal tumor models.

In one set of experiments, Balb/c mice were inoculated with CT26 tumorcells on day 0 and/or rechallenged with a second inoculation of CT26tumor cells at day 30. Following 5 days of tumor growth, when tumorsreached a diameter of 4-5 mm, mice were treated with either CD40 agonistantibodies, CSF1R (CD115) blocking antibodies, the combination of thosetwo antibodies, or the mCD115-Fc-CD40L chimeric protein. Treatments wererepeated on day 7.

The tumor growth for each treatment group was assessed as shown in FIG.11A. Specifically, the untreated mice developed tumors quickly.Treatment with either the CD40 agonist antibodies, CSF1R (CD115)blocking antibodies, or the combination of those two antibodies appearedto slightly delay the development of tumors. In comparison, treatingmice with the mCD115-Fc-CD40L chimeric protein significantly preventedand/or delayed the development of tumors. The above data suggests thattreatments with a CSF1R(CD115)-Fc-CD40L chimeric protein creates animmune memory effect in vivo. Thus, the treated animal is able to laterattack tumor cells and/or prevent development of tumors whenrechallenged after an initial treatment with the chimeric protein.

The overall survival percentage of mice through 50 days after tumorinoculation was also assessed. All of the untreated mice died within 30days after tumor inoculation. Other groups of mice treated with the CD40agonist antibodies, CSF1R (CD115) blocking antibodies, or thecombination of those two antibodies prolonged survival but still lessthan 25% of those mice survived to 50 days after tumor inoculation.Significantly, more than 70% of the mice treated with themCD115-Fc-CD40L chimeric protein survived past 50 days post tumorinoculation as shown in FIG. 11B. As shown in FIG. 11C, treatment withthe chimeric protein resulted in significantly higher tumor rejectionthan treatment with CD40 agonist antibodies, CSF1R (CD115) blockingantibodies, or a combination of the two antibodies.

Example 12 Immunophenotyping of Lymphocyte Populations from TumorBearing Mice

Immune phenotyping was also performed by analyzing splenocytes, lymphnode cells, and tumor infiltrating lymphocytes on day 13 post tumorinoculation. As shown in FIG. 12A, mice treated with the mCD115-Fc-CD40Lchimeric protein exhibited increased frequencies of both CD4+ and CD8+ Tcells in the spleen, but not in the lymph node or tumor as compared tountreated mice. Additionally, mice treated with the chimeric proteinexhibited a decrease in the proportion of CD4+CD25+ cells in the spleenand tumors suggesting that the chimeric protein reduces regulatory Tcells (FIG. 12B). Notably, despite a non-significant increase in theproportion of total CD8+ cells within the tumor (FIG. 12A), asignificant increase in the proportion of CD8+ T cells specific for theAH1 tumor antigen (by tetramer staining) were detected in mice treatedwith mCD115-Fc-CD40L chimeric protein (FIG. 12C), suggesting thechimeric protein enhanced tumor recognition by CD8+ T cells.

To assess CD40 receptor activation by the mCD115-Fc-CD40L chimericprotein, induction of CD19+ cells and IL-15Rα positive cells by thechimeric protein were analyzed. As shown in FIG. 12D, a significantincrease in CD19+ cells was observed in the splenocytes of mice treatedwith the chimeric protein. This increase in CD19+ cells was not observedin the lymph nodes or tumor cells. Further, there was also a significantincrease in IL-15Rα positive cells in the splenocytes of mice treatedwith the chimeric protein (FIG. 12E). Again, the increase was notobserved in the lymph nodes or tumor cells.

Example 13 Reduced Toxicity of CSF1R-Fc-CD40L Compared to CSF1R and CD40Antibodies

The in vivo studies also surprisingly demonstrated that themCD115-Fc-CD40L chimeric protein exhibited enhanced safety profiles.Specifically, mice treated with the CD40 agonist antibody and theCD40+CD115 antibody combination treatment were observed to developsignificant diarrhea and weight loss over the course of the experiment.In mice treated with the CD40 agonist antibody, a gut inflammatoryresponse was initiated leading to diarrhea and weight loss, which wasthen significantly exacerbated by combination treatment with CD115blockade. Mice in the antibody combination (CD115+CD40 antibody) grouplost >25% of their body weight (FIG. 13B), had a moribund appearance andin some cases this inflammatory response was lethal (see FIG. 13A). Incontrast, mice treated with the mCD115-Fc-CD40L chimeric proteinappeared healthy, did not develop any signs of diarrhea or weight loss,and behaved normally (FIG. 13A and FIG. 13B).

Altogether, these data indicate that the treatment with themCD115-Fc-CD40L chimeric protein led to significantly higher rates ofcomplete tumor rejection than CD115 blocking antibodies alone, CD40agonist antibodies alone, or the combination of CD115 blocking and CD40agonist antibodies. Further still, treatment with the chimeric proteinprovided enhanced safety profiles compared to treatment with theantibodies, which were highly toxic when co-administered to mice andcaused lethal gut inflammation and diarrhea.

Example 14 Characterization of the Contribution of an Fc Domain in aLinker to Functionality of Chimeric Proteins

In this example, the contribution of an Fc domain in a linker tofunctionality of chimeric proteins of the present invention was assayed.Here, a PD1-Fc-OX40L was used as a model for Fc-containing chimericproteins. Thus, the data presented below is relevant to chimericproteins of the present invention.

In its native state, PD1 exists as monomer whereas OX40Ls tend todimerize due to electrostatic interactions between the OX40L domains; Fcdomains associate with each other via disulfide bonds. Together, severalinter-molecular interactions may contribute to the quaternary structureof PD1-Fc-OX40L. There are, at least, four potential configurations ofPD1-Fc-OX40L, with the chimeric protein existing as a monomer, a dimer,a trimer, or a hexamer. See, FIG. 14.

The existence of monomeric and dimeric configurations of the chimericprotein was tested by exposing chimeric proteins to reducing andnon-reducing conditions and then running the proteins on SDS-PAGE. Undernon-reducing conditions (Reduced: “−”), the chimeric protein migrated inSDS-PAGE at about 200 kDa. Here, Western blots were probed withantibodies directed against PD1, Fc, or OX40L in, respectively, theleft, middle, and right blots shown in FIG. 15. Since, the predictedmonomeric molecular weight of the chimeric protein is 57.6 kDa, the 200kDa species was expected to be, at least a dimer. However, under reducedconditions (Reduced: “+”), which reduces disulfide bonds (e.g., betweenFc domains), the chimeric protein migrated in SDS-PAGE at about 100 kDa.Since the 100 kDa species was heavier than expected, it was predictedthat the extra mass was due to glycosylation. Finally, chimeric proteinswere treated with Peptide-N-Glycosidase F (PNGaseF “+”) and run onSDS-PAGE under reduced conditions. Under these conditions, the chimericprotein migrated at about 57.6 kDa. These data suggest that the chimericprotein is glycosylated and exists naturally, at least, as a dimer; withdimerization likely due to disulfide bonding between Fc domains.

SDS-PAGE gel methods do not accurately predict the molecular weight forhighly charged and/or large molecular weight proteins. Thus, chimericproteins were next characterized using Size Exclusion Chromatography(SEC). Unlike SDS-PAGE, in which the negatively-charged SDS reducescharge-based interactions between peptides, SEC does not use detergentsor reducing agents. When the PD1-Fc-OX40L chimeric protein was run onSEC, none of the peaks were around 200 kDa. This suggests, thatnatively, the chimeric protein does not exist as a dimer. Instead, apeak having a size greater than 670 kDa was detected. See, FIG. 16. Thisand the prior data suggests that the PD1-Fc-OX40L chimeric proteinexists as a hexamer in its native state.

As shown above, when run on SDS-PAGE under non-reducing conditions orunder reducing conditions, SDS in the sample and/or running bufferconverts the hexameric PD1-Fc-OX40L chimeric protein into a predominantdimer or monomer, respectively, in the absence and presence of areducing agent. See, FIG. 17 (left gel). When run on native PAGE, whichlacks SDS, and in the absence of a reducing agent, the chimeric proteinexists as a hexamer. However, when run on native PAGE and in thepresence of a reducing agent (which reduces disulfide bonds) thechimeric protein migrated heavier than expected; as shown in FIG. 17(right gel, lane #2), with the chimeric protein failed to substantiallymigrate out of the loading well. This data suggests that the chimericprotein has oligomerized into a higher order protein. Thus, in chimericproteins, disulfide bonding appears to be important for controllinghigher-order oligomerization.

To further confirm this, chimeric proteins lacking an Fc domain wereconstructed, e.g., “PD1-No Fc-OX40L”. Such chimeric proteins will nothave the disulfide bonding which occurs between Fc domains in thechimeric proteins described previously. As shown in FIG. 18, whenchimeric proteins lacking Fc domains are run on native PAGE, none of theprotein substantially migrated out of its loading well (lane #1 to #4show increasing loading concentrations of PD1-No Fc-OX40L); again,suggesting that the “No Fc” chimeric proteins have formed aconcatamer-like complex comprising numerous proteins. Thus, omission ofthe Fc domain in a chimeric protein leads to formation of proteinaggregates. These data indicate that disulfide bonding, e.g., between Fcdomains on different chimeric proteins, stabilizes the chimeric proteinsand ensures that they each exist as a hexamer and not as a higher orderprotein/concatemer. In other words, the Fc domain surprisingly putsorder to chimeric protein complexes. Lane #1 to #4, respectively,include 2.5 μg, of PD1-No Fc-OX40L, 5 μg of PD1-No Fc-OX40L, 7.5 μg ofPD1-No Fc-OX40L, and 10 μg of PD1-No Fc-OX40L.

Shown in FIG. 19, is a model summarizing the above data and showing howa hexamer and concatamers form from chimeric proteins of the presentinvention. The exemplary chimeric protein (PD1-Fc-OX40L) naturally formsinto a hexamer (due to electrostatic interactions between the OX40Ldomains and dimerization by Fc domains). However, in the absence of thecontrolling effects of disulfide bonding between Fc domains, underreduced conditions for the PD1-Fc-OX40L protein and due to the absenceof Fc domains in the PD1-No Fc-OX40L, these latter chimeric proteinsform concatamers.

Additionally, chimeric proteins were constructed in which the Fc domain(as described herein) was replaced with Ficolin (which lacks cysteineresidues necessary for disulfide bonding between chimeric proteins). Aswith the “No Fc” chimeric proteins and chimeric proteins comprising anFc and run on native PAGE and in the presence of a reducing agent (bothof which formed aggregates that do not migrate into a gel), chimericproteins comprising Ficolin appear to also form higher-order latticeswhich did not migrate into a gel. These data reinforce the conclusionthat disulfide binding is important for proper folding and function ofchimeric proteins of the present invention.

Finally, chimeric proteins were prepared using coiled Fc domains(CCDFc). Very little purified protein was delivered under functionalevaluation.

Accordingly, including an Fc domain in a linker of a chimeric protein(which is capable of forming disulfide bonds between chimeric proteins),helps avoid formation of insoluble and, likely, non-functional proteinconcatamers and/or aggregates.

Example 15 Production of Additional CSF1R-Containing Chimeric ProteinsComprising Extracellular Domains of Other Type II Proteins

In this example, additional chimeric proteins of the present inventionare described. Such additional chimeric proteins will be made similar tohow the CSF1R-Fc-CD40L chimeric proteins were made, e.g., as describedabove in the Detailed Description and in U.S. 62/464,002, the contentsof which are hereby incorporated by reference in its entirety.

These additional chimeric proteins will have the general formula: ECD1-Joining Linker 1-Fc Domain-Joining Linker 2-ECD 2, in which ECD 1 isthe extracellular domain of CSF1R and ECD 2 is the extracellular domainof a type II protein, other than CD40L. Exemplary type II proteinsinclude 4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L, TL1A, and TRAIL. Thesechimeric proteins may lack one or both of the joining linkers.

These chimeric proteins may lack one or both of the joining linkers.Exemplary Joining Linker 1s, Fc Domains, and Joining Linker 2s aredescribed above in Table 1; modular linkers useful for forming chimericproteins and comprising specific Joining Linker 1s, Fc Domains, andJoining Linker 2s are shown in FIG. 20.

Alternately, the additional chimeric proteins will be fusion proteinshaving the general formula: N terminus-(a)-(b)-(c)-C terminus, in which(a) is CSF1R, (b) is a linker comprising at least a portion of a Fcdomain, and (c) is the extracellular domain of a type II protein otherthan CD40L. Exemplary type II proteins include 4-1BBL, CD30L, FasL,GITRL, LIGHT, OX40L, TL1A, and TRAIL.

The amino acid sequence for 4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L,TL1A, and TRAIL, respectively, comprises SEQ ID NO: 9, 11, 13, 15, 17,6, 21, and 23. The amino acid sequence for extracellular domain of4-1BBL, CD30L, FasL, GITRL, LIGHT, OX40L, TL1A, and TRAIL, respectively,comprises SEQ ID NO: 10, 12, 14, 16, 18, 7, 22, and 24. The amino acidsequence for CSF1R comprises SEQ ID NO: 1 and the extracellular domainof CSF1R comprises SEQ ID NO: 2. The chimeric proteins may comprise avariant of the above-mentioned sequences, e.g., at least about 95%identical to an above-mentioned sequence.

Exemplary linkers are described above in Table 1; modular linkers usefulfor forming chimeric proteins and comprising specific Joining Linker 1s,Fc Domains, and Joining Linker 2s are shown in FIG. 20.

Accordingly, the present invention further includes the followingadditional chimeric proteins and methods using the additional chimericproteins (e.g., in treating a cancer and/or treating an inflammatorydisease): CSF1R-Fc-4-1BBL, CSF1R-Fc-CD30L, CSF1R-Fc-FasL,CSF1R-Fc-GITRL, CSF1R-Fc-LIGHT, CSF1R-Fc-OX40L, CSF1R-Fc-TL1A, andCSF1R-Fc-TRAIL.

The additional chimeric proteins will be characterized as describedabove for CSF1R-Fc-CD40L in Examples 1 to 13, albeit with reagents(e.g., binding partners, recombinant target cells, and cancer cell/tumortypes) that are specific to the additional chimeric proteins rather thanas needed for characterizing CSF1R-Fc-CD40L. Thus, using CSF1R-Fc-4-1BBLas an example, characterizations of CSF1R-Fc-4-1BBL akin to Example 2can be performed using anti-CSF1R, anti-Fc, and anti-4-1BBL antibodiesrather than the anti-CSF1R, anti-Fc, and anti-CD40L antibodies neededfor CSF1R-Fc-CD40L.

As with the CSF1R-Fc-CD40L chimeric proteins, the additional chimericproteins will be effective in treating a cancer and/or treating aninflammatory disease by blocking CSF1R (which inhibits the transmissionof an immune inhibitory signal) and enhancing, increasing, and/orstimulating the transmission of an immune stimulatory signal viaactivating the receptor/ligand of one of 4-1BBL, CD30L, FasL, GITRL,LIGHT, OX40L, TL1A, and TRAIL. Moreover, the additional chimericproteins will be effective in treating a cancer and/or an inflammatorydisease yet without the toxicity resulting from treatments comprising aplurality of antibodies, e.g., a CSF1 or IL-34 blocking antibody and anagonist antibody for the receptor/ligand of one of 4-1BBL, CD30L, FasL,GITRL, LIGHT, OX40L, TL1A, and TRAIL.

1. A heterologous chimeric protein comprising: (a) a first domaincomprising a portion of colony stimulating factor 1 receptor (CSF1R)that is capable of binding a CSF1R ligand; (b) a second domaincomprising a portion of CD40 Ligand (CD40L) that is capable of binding aCD40L receptor; and (c) a linker linking the first domain and the seconddomain.
 2. The heterologous chimeric protein of claim 1, wherein thefirst domain comprises substantially all of the extracellular domain ofCSF1R and the second domain comprises substantially all of theextracellular domain of CD40L.
 3. (canceled)
 4. The heterologouschimeric protein of claim 1, wherein the chimeric protein is capable of:(a) reducing or eliminating an immune inhibitory signal when the portionof CSF1R is bound to its ligand and/or (b) increasing or activating animmune stimulatory signal when the portion of CD40L is bound to itsreceptor. 5-6. (canceled)
 7. The heterologous chimeric protein of claim1, wherein the chimeric protein is capable of contemporaneously bindingthe CSF1R ligand and the CD40L receptor, wherein the CSF1R ligand isCSF1 or IL-34 and the CD40L receptor is CD40. 8-10. (canceled)
 11. Theheterologous chimeric protein of claim 1, wherein the chimeric proteinexhibits enhanced anti-tumor effects compared to CD40 agonist antibodiesand/or CSF1R antagonistic antibodies.
 12. The heterologous chimericprotein of claim 1, wherein the chimeric protein is capable ofincreasing or preventing a decrease in a sub-population of CD4+ and/orCD8+ T cells.
 13. The heterologous chimeric protein of claim 1, whereinthe chimeric protein is capable of enhancing tumor killing activity by Tcells.
 14. The heterologous chimeric protein of claim 1, wherein thechimeric protein is capable of providing a sustained immunomodulatoryeffect.
 15. The heterologous chimeric protein of claim 1, wherein thechimeric protein is capable of causing activation of antigen presentingcells. 16-23. (canceled)
 24. The heterologous chimeric protein of claim1, wherein the linker is a polypeptide selected from a flexible aminoacid sequence, an IgG hinge region, or an antibody sequence.
 25. Theheterologous chimeric protein of claim 24, wherein the linker compriseshinge-CH2-CH3 Fc domain derived from IgG4.
 26. The heterologous chimericprotein of claim 25, wherein the hinge-CH2-CH3 Fc domain is derived fromhuman IgG4.
 27. The heterologous chimeric protein of claim 1, whereinthe chimeric protein is expressed by a mammalian host cell as asecretable and functional single polypeptide chain.
 28. The heterologouschimeric protein of claim 1, wherein the portion of CSF1R is at least95% identical to the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:2.
 29. The heterologous chimeric protein of claim 1, wherein the portionof CD40L is at least 95% identical to the amino acid sequence of SEQ IDNO: 3 or SEQ ID NO:
 4. 30. The heterologous chimeric protein of claim 1,wherein the linker comprises an amino acid sequence that is at least 95%identical to the amino acid sequence of SEQ ID NO: 25, SEQ ID NO: 26, orSEQ ID NO:
 27. 31-49. (canceled)
 50. A method for treating cancer or aninflammatory disease comprising administering an effective amount of apharmaceutical composition to a subject in need thereof, thepharmaceutical composition comprising a heterologous chimeric proteincomprising: (a) a first domain comprising a portion of colonystimulating factor 1 receptor (CSF1R) that is capable of binding a CSF1Rligand, (b) a second domain comprising a portion of CD-40 ligand (CD40L)that is capable of binding an CD40L receptor, and (c) a linker linkingthe first domain and the second domain.
 51. The method of claim 50,wherein the subject's T cells are activated when bound by the seconddomain of the heterologous chimeric protein and: (a) one or more tumorcells are prevented from transmitting an immunosuppressive signal whenbound by the first domain of the heterologous chimeric protein, (b) aquantifiable cytokine response in the peripheral blood of the subject isachieved, and/or (c) tumor growth is reduced in the subject in needthereof as compared to a subject treated with CD40 blocking antibodiesand/or CSF1 or IL-34 blocking antibodies. 52-64. (canceled)
 65. Arecombinant fusion protein comprising a general structure of:N terminus-(a)-(b)-(c)-C terminus, wherein: (a) is a first domaincomprising an extracellular domain of CSF1R that is at least 95%identical to the amino acid sequence of SEQ ID NO: 2 and is capable ofbinding a CSF1R ligand, (b) is a linker linking the first domain and thesecond domain and comprising a hinge-CH2-CH3 Fc domain derived fromhuman IgG4, and optionally one or more joining linker sequencesindependently selected from SEQ ID 28 to 74, and (c) is a second domaincomprising an extracellular domain of CD40 ligand (CD40L) that is atleast 95% identical to the amino acid sequence of SEQ ID NO: 4 and iscapable of binding an CD40L receptor.
 66. The recombinant fusion proteinof claim 65, wherein the linker comprises a sequence which is at least95% identical to the amino acid sequence of SEQ ID NO: 25, SEQ ID NO:26, or SEQ ID NO:
 27. 67-70. (canceled)